




KONGERIKET NORGE
The Kingdom of Norway



Bekreftelse på patentsøknad nr

Certification of patent application no

2000 0163

Det bekreftes herved at vedheftede dokument er nøyaktig utskrift/kopi av ovennevnte søknad, som opprinnelig inngitt 2000.01.12

It is hereby certified that the annexed document is a true copy of the above-mentioned application, as originally filed on 2000.01.12

2001.01.25

Freddy Strømmen

Freddy Strømmen
Seksjonsleder

Ellen B. Olsen

Ellen B. Olsen



PATENTSTYRET
Styret for det industrielle rettsvern

12. januar 2000
TG/eah
O.nr. 134642

16
PATENTSTYRET

12 JAN 00 200163

ANSØKER:

BIOTEC ASA

Strandgt. 3

N-9008 Tromsø, Norge

OPPFINDERE:

Opplyses senere

TITTEL:

Varmelabil uracil-DNA-glykosylase samt anvendelse
derav.

Cod Uracil-DNA Glycosylase, Gene coding therefore,
Recombinant DNA Containing said Gene or Operative Parts
thereof, a Method for preparing said Protein and the use of
said protein or said operative parts thereof in monitoring
or controlling PCR

10 Field of invention

The present invention relates to a novel enzyme present in
cod liver, a DNA sequence encoding the enzyme or operative
parts thereof, a novel recombinant DNA comprising the gene
or the operative parts thereof, a method of preparing the
enzyme from cod liver and from bacteria carrying the gene,
the bacteria carrying the gene per se, and the use of the
protein in monitoring and/or controlling PCR or related
reaction systems.

20 Description of prior art

Uracil in DNA may result from the incorporation of dUTP
instead of dTTP during replication (Refs) or from
deamination of cytosine in DNA (Lindahl & Nyberg, 1974).
The latter results in a mutation at the next round of
replication. The enzyme Uracil-DNA glycosylase (UDG, EC
3.2.2.3) functions as a repair enzyme for such damage to
DNA in that the uracil base is excised from the DNA
backbone (Lindahl 1994), creating an apyrimidinic site
which is recognised by other DNA repair enzymes. This
enzyme is crucial to maintain DNA integrity, and has
therefore been found in a variety of organisms; virus,
prokaryotes and eukaryotes (Savva et al., 1995)

Several classes of uracil-DNA glycosylases (UDG) have been
described. ("UNG encoded by the UNG-gene comprises the
majority of cellular UDG-activity", Slupphaug, 1991 #187.)
The major cellular form of UDG is UNG encoded by the UNG-
gene (Slupphaug, 1991 #187). Other classes comprises the

cyclin like human UDG2 (Muller, 1991 #34) (Muller Weeks, 1996 #36), the single strand selective monofunctional UDG SMUG1 from human *Xenopus* (Haushalter, 1999 #188) and the G/T:U specific mismatch DNA glycosylase (MUG) (Gallinari, 1996 #71).

Uracil-DNA glycosylase (UNG or UDG) catalyses the hydrolysis of the N-glycosylic bond between the deoxyribose sugar and the base in uracil-containing DNA, and was first isolated and characterized from *Escherichia coli* [1]. This is the first step in the base excision repair (BER) pathway of removing uracil from DNA [2], and the apyrimidinic site generated is thereafter repaired by an AP endonuclease, phosphodiesterase, DNA polymerase and DNA ligase (other enzymes) in the BER pathway [3-5].

Several classes of uracil-DNA glycosylases (UDG) have been described. The major cellular form of UDG is UNG encoded by the UNG-gene [6]. Other classes consist of cyclin-like human UDG2 [7,8], single-strand selective monofunctional UDG (SMUG1) from human and *Xenopus* [9], G/T:U specific mismatch DNA glycosylase (MUG) isolated from *E. coli* [10,11] and *Thermotoga maritima* UDG (TMUDG) [12]

UNG is a monomeric protein, about 25-35 kD in size. It is not dependent on any cofactors or divalent cations and is highly conserved among different species [13]. UNG is, however, affected by ionic strength. The UNG enzyme has been shown to act in a processive "sliding mechanism", where it locates sequential uracil-residues prior to dissociation from DNA [14,15], and a distributive "random hit" mechanism [16]. UNG has previously been isolated and characterised from rat liver [17-19], human cells and tissues [20-28], calf thymus [29,30], slime mold [31], yeast [32], plants [33,34], brine shrimp [35], procaryotes [1,36-45] and viruses [46,47].

In human and rat both a mitochondria and nuclear UNG have been isolated [18,25]. In human (and mouse) cells these two are encoded by the same gene (UNG) [48,49]. By two different transcription start sites and alternative
 5 splicing, two forms are generated which differ only in the N-terminal signal sequence, which targets the enzyme to the nucleus (UNG2) and mitochondria (UNG1), respectively [49]. Recently, several studies have been done to further study the N-terminal signal sequence and targeting of UNG to the
 10 nucleus and mitochondria [50-52], revealing the nuclear UNG2 to be phosphorylated [26]. The crystal structures of UNG from human, herpes simplex virus and *E. coli* have been solved [53-55]. The active site residues are conserved and the mode of action in these enzymes seems to be the same
 15 with a nucleotide flipping mechanism to remove uracil from DNA [56,57].

Enzymes from cold adapted organisms, such as the Atlantic cod (*Gadus morhua*), have to compensate for the reduction of
 20 chemical reaction rates at low temperatures in order to maintain sufficient metabolic activities. This can be achieved by higher transcriptional/translational levels or improved catalytic efficiency (k_{cat}/K_M). Higher catalytic efficiencies can be reached by a more flexible structure,
 25 compared to their mesophile counterparts, which provides enhanced ability to undergo conformational changes during catalysis. The reduced stability to pH, temperature and denaturing agents is regarded as a consequence of the conformational flexibility [58].

:30

The present invention concerns the purification and characterization of a heat-labile uracil-DNA glycosylase from a cold-adapted organism, and which has utility as an enzyme efficient in carry-over prevention in DNA-copying
 35 reactions (PCR, LCR etc.). The enzyme isolated according to the present invention has similar characteristics as previously described UNGs with respect to molecular weight, isoelectric point, pH and NaCl-optimum. However, the

enzyme according to the present invention has been shown to be more pH-labile and heat-labile and has a higher relative activity at low temperatures, compared to a recombinant mesophilic human UNG, making it a better candidate in carry-over prevention tests as indicated supra.

UDG from *Escherichia coli* has been commercially available for use in carry-over prevention when amplifying DNA material.

Various techniques may be employed to amplify specific DNA sequences on basis of a DNA template. Common techniques are the polymerase chain reaction (PCR) system (US patent Nos. 4.683.195; 4.683.202; and 4.965.188), the ligase amplification system (PCT patent publication No. 89/09835), the self-sustained sequence replication system (EP No. 329.822 and PCT patent publication No. 90/06995), the transcription-based amplification system (PCT patent publication No. 89/01050 and EP No. 310.229) and the Q β RNA replicase system (US patent No. 4.957.858). These techniques are very sensitive in that they may produce detectable DNA amounts from very few copies of a target DNA sequence. Accordingly the techniques are very sensitive to contamination by DNA from the environment. The major source of contamination is products from previously performed up-scaling reactions, e.g. PCR reactions (Kwok & Higuchi 1989).

To overcome this problem a method to discriminate between target DNA and contaminating DNA from prior reactions, e.g. PCR product DNA, has been developed (Longo et al., 1990, Hartley, 1990). In essence, all amplification reactions are carried out using dUTP to replace dTTP thus incorporating uracil into DNA in place of thymidine. All subsequent reaction mixtures are then treated with UDG. A following heat treatment degrades the contaminating DNA by hydrolysis of the phosphodiester bond at abasic sites.

Also, the heat treatment is supposed to inactivate the UDG enzyme.

However, the UDG enzyme from *E. coli* is not completely inactivated by heat treatment, and the inactivation is not completely irreversible (Longo et al., 1990). This affects the upscaling reaction, e.g. PCR reaction, product integrity, since the products are degraded by residual UDG enzyme activity. In order to avoid this, the subsequent addition of enzyme inhibitor to UDG has been used (Frasier et al., 1994).

However, it would be preferable to avoid using the subsequent inhibitor because this represents an extra step in the reaction procedure, residual contamination by the inhibitor may be present in subsequent reactions, and the purchase of inhibitor represents an extra cost when performing a PCR reaction as disclosed supra.

Thus it would be preferable to use an UDG enzyme which is certain to be destroyed/inactivated by the heat treatment following the PCR reaction, thus avoiding the addition of specific chemical inhibitors for the UDG enzyme.

25 Objects of the invention

It is an object of the present invention to provide a novel UDG enzyme which is functional in carry-over prevention techniques for DNA amplification reactions, e.g. PCR, indicated supra, and which is completely and irreversibly inactivated by the heat treatment normally performed in PCR reaction cycles.

Furthermore it is an object of the present invention to provide a DNA sequence coding for such an enzyme or an active part thereof, a vector or vector system (e.g. a virus, a plasmid, a cosmid, etc.) carrying such a DNA sequence and a microorganism including such a vector.

It is also an object of the present invention to provide a method for efficient production of the enzyme or an active part thereof by using genetic engineering techniques.

5 Detailed description of the invention

Enzymes from cold adapted organisms living in cold habitats, such as the Atlantic cod (*Gadus morhua*), have to compensate the reduction of chemical reaction rates at low temperatures to maintain sufficient metabolic activities.

- 10 This can be done by a higher transcription/translational level, or improved catalytic efficiency (k_{cat}/K_M). This higher efficiency is reached with a more flexible structure, compared to their mesophile counterparts, which provides enhanced ability to undergo conformational changes
- 15 during catalysis. The reduced stability to pH, temperature and denaturing agents is regarded as a consequence of the conformational flexibility (Feller, 1997 #157).

- In view of the disadvantages with contaminations of UDG according to prior art in carry-over prevention procedures when amplifying DNA sequences (PCR, LCR) it would be very convenient to provide a UDG enzyme which was 100% degraded by simple heat treatment. It has now been found that a UDG enzyme isolated from cod has this valuable property. The
- 20 cod-UDG enzyme isolated according to the present invention has a similar molecular weight, isoelectric point, pH- and NaCl-optimum as previously described UNGs, but the present cod-UNG is more pH- and heat-labile and has a higher relative activity at low temperatures as compared to a
- 25 recombinant mesophilic human UNG.
- 30

- Infra is disclosed an isolation procedure for the relevant cod UNG protein according to the invention as well as isolation of DNA coding for this protein and its use in
- 35 microorganisms for producing recombinantly the relevant UNG enzyme according to the invention is disclosed.

MATERIAL AND METHODS

Q-sepharose FF, S-sepharose FF, Heparin sepharose HP (Hi-trap 5 ml), Poly-U-sepharose 4B, Superdex 75 HR10/30, Phast system and Phast IEF gels (3-9) and LMW gel filtration calibration kit were obtained from Amersham Pharmacia Biotech (Uppsala, Sweden). Deoxy[5-³H]uridine 5'-triphosphate (19.3 Ci/mmol) was purchased from Amersham (U.K). Uracil-DNA glycosylase inhibitor (Ugi) was obtained from New England Biolabs (Beverly, MA), enzymes were purchased from Promega (Madison, WI). Protease inhibitors, calf-thymus DNA (D-1501), uracil, deoxyuridine and deoxyuridine-monophosphate were purchased from Sigma (St. Lois, MO). All other reagents and buffers were purchased from Sigma and Merck (Darmstadt, Germany).

Purification of cUNG

Preparation of crude extract and all purification steps were performed at 4°C.

20 Preparation of crude extract

To 600 ml extract buffer (25 mM Tris/HCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, pH 8.0 (25°C) 200 g of fresh cod liver was added and homogenized in an Atomix

homogenizer (MSE, England). Before homogenization, the following protease inhibitor mix was added to the extract buffer: 1 mM PMSEF, 1 μM pepstatine, 1 μM leupeptine, 10 μM TPCK and 10 μM TLCK (final concentrations). The homogenate was centrifuged at 28,000 g for 15 min and the supernatant was filtered through glasswool. Finally glycerol was added to 30 % (v/v), and the cod liver crude extract was frozen at -70°C.

Q-sepharose Fast Flow

One liter crude extract was diluted with 1 liter buffer A (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1% glycerol, pH 8.0) (Fraction 1). The sample was applied in two portions (1 liter each) on a Q-sepharose FF column (5.0/15), equilibrated with buffer A, and then washed with 250 ml buffer A, using a flow-rate of 10 ml/min. Proteins bound to the column were eluted with 200 ml buffer A + 1.0 M NaCl, and the column was re-equilibrated with buffer A before the next part of the sample was applied, as mentioned above. The UNG-containing flowthrough and wash fractions from both two runs were pooled (Fraction 2, 2340 ml).

S-sepharose Fast Flow

Fraction 2 was applied to a S-Sepharose FF column (1.6/10) equilibrated in buffer A, flow rate 10 ml/min. The column was washed with 300 ml buffer A + 60 mM NaCl, and eluted using a 200 ml linear gradient of 0.06-0.4 M NaCl in buffer A, flow-rate 5 ml/min. UNG-containing fractions were pooled (55 ml) and dialyzed overnight in buffer A (Fraction 3).

Heparine sepharose High Performance

Fraction 3 was applied to a heparine sepharose HP Hi-Trap column (1.6/2.5) equilibrated in buffer A. The column was washed with 50 ml buffer A + 60 mM NaCl and was eluted in a 50 ml linear gradient of 0.06-0.4 M NaCl in buffer A, flow-rate 1 ml/min. UNG-containing fractions were pooled (Fraction 4, 20 ml).

30 Poly-U sepharose (4B)

Fraction 4 was then diluted 5 times in buffer A, and applied to a poly-U sepharose column (1.6/10) equilibrated in buffer A. The column was washed with 60 ml buffer A + 60

mM NaCl and was eluted in a 200 ml linear gradient of 0.06-0.4 M NaCl in buffer A, flow-rate 1ml/min. UNG- containing fractions were pooled (fraction 5, 70 ml).

5 Superdex75

Fraction 5 was concentrated to 200 μ l using Ultrafree15 and Ultrafree-MC ultracentrifugation filters (Millipore), cutoff 5K, and applied on the gel filtration column (HR 1.0/30) equilibrated in buffer A, with a flow-rate of 0.5 ml/min. Fractions (350 μ l) were collected, and those containing UNG-activity were pooled (fraction 6, 3 ml).

Preparation of substrate by nick-translation

^3H -dUMP DNA was prepared by nick-translation and polymerase chain reaction (PCR). The nick translated substrate was made in a total volume of 1 ml and contained 50 mM Tris/HCl, pH 7.2, 10 mM MgSO_4 , 1 mM DTT, 250 μ g calf thymus DNA (purified by phenol/chloroform extraction and ethanol precipitated prior to use), 0.1 mM dATP, dCTP, dGTP and dUTP, where 3 μ M of the dUTP was [^3H]-dUTP (19.3 Ci/mmol). Then 0.1ng (5.35×10^{-4} U) DNase I (bovine pancreas, Promega) was added and 30 seconds later 25 U of *E. coli* DNA polymerase, and the nick-translation mix was incubated at 21°C for 24 hours. The nick-translated DNA was purified by phenol/chloroform extraction, and ethanol precipitation. DNA was resuspended in 50 μ l TE-buffer and purified with a NAP-5 column (AP Biotech) equilibrated in TE-buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0) to remove unincorporated nucleotides. Specific activity of the Nick-substrate was 1.8×10^5 dpm/ μ g (425 cpm/pmol).

Preparation of substrate by PCR

The PCR-produced substrate was used for all characterization experiments and consisted of a 761 bp

fragment generated from cationic trypsinogen from Atlantic salmon (*Salmo salar*) [59]. The PCR was carried out in a volume of 50 μ l in a Perkin Elmer Cetus thermocycler. The PCR-mix contained 10 mM Tris/HCl, pH 8.3, 50 mM KCl, 6 mM MgCl₂, 0.37 mM dATP, dCTP, dGTP and dUTP, where 10.4 μ M of dUTP was [³H]-dUTP (17.0 Ci/mmol, Amersham), 700 pg template DNA (sstrpiV in a pgem7zt-vector), 2.5 μ M of upstream and downstream primers and 2 U Taq-polymerase (Roche, Switzerland). The PCR-reaction was done by 30 cycles of 94°C for 1 min, 45°C for 1 min and 72°C for 1 min. Then an additional 2 U of Taq-polymerase was added and the PCR-reaction continued with 30 new cycles as described. The PCR-substrate was purified with QIAquick PCR-purification kit (Qiagen) as described by manufacturer, and eluted in 50X diluted TE-buffer, pH 8.0. Specific activity of the PCR-substrate was 5.9×10^5 dpm/ μ g (451 cpm/pmol). All characterization experiments were done using the PCR-substrate.

20 Detection of uracil-DNA glycosylase activity (Standard assay)

Uracil-DNA glycosylase activity was measured in a final volume of 20 μ l, containing 70 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 100 μ g/ml BSA and 230 ng nick-substrate or 71 ng PCR-substrate. The reaction mixture was incubated 10 min at 37°C, and terminated with the addition of 20 μ l of ice cold single stranded calf thymus DNA (1 mg/ml) and 500 μ l 10% (w/v) TCA. Samples were incubated on ice for 15 min, and centrifuged at 16,000 g for 10 min. Supernatants with acid soluble ³H-uracil were analyzed using a liquid scintillation counter.

One unit of activity is defined as the amount of enzyme required to release 1 nmol of acid soluble uracil per minute at 37°C.

Analysis of assay products with thin layer chromatography

Reaction products after assays were mixed with 20 nmol uracil, deoxyuridine and deoxyuridine- monophosphate. Thin layer chromatography was performed according to the method by Wang and Wang, using polyamide layer plates (BDH), and tetrachloromethane, acetic acid and acetone (4:1:4, by volume) as solvent [60]. Spots detected under UV-light were cut out of the plate and radioactivity measured in a liquid scintillation counter.

Molecular-weight determination

The molecular weight was determined by gel-filtration, and was performed with a Superdex 75 column (1.0/30) equilibrated in a buffer containing 25 mM Tris/HCl, 1.0 M NaCl, 1 mM EDTA, 1 % glycerol, pH 8.0. The flow-rate was 0.5 ml/min, and activity was measured in the fractions collected (250 μ l). Bovine serum albumin (BSA, 67 kD), ovalbumin (43 kD), chymotrypsinogenA (25 kD) and ribonucleaseA (13.7 kD) were used as standards. Blue dextran and sodium chloride were used to determine void- (V_0) and intrinsic volume (V_i), respectively.

Protein determination

Protein concentrations were determined with Coomassie® Protein Assay Reagent G-250 (Pierce, New York, NY) by the method of Bradford [61], with the microtiter plate protocol as described by manufacturer, using bovine serum albumin (BSA) as a standard.

Isoelectric point determination

Isoelectric point determination was done with the Phast-system, isoelectric focusing gel 3-9 and silver stained according to methods described by manufacturer. Standards

used were phycocyanin (4.45, 4.65, 4.75), β -lactoglobulin B (5.10), bovine carbonic anhydrase (6.00), human carbonic anhydrase (6.50), equine myoglobin (7.00), human hemoglobin A (7.10), human hemoglobin C (7.50), lentil lectin (7.8, 8.0, 8.2), cytochrome c (9.6), (IEF Standards pI range 4.45-9.6, BIO-RAD). After focusing, the gel was cut into 2 mm pieces and each incubated in 250 μ l extraction buffer (50 mM Tris/HCl, 0.2 M NaCl, 1 mM DTT, 1 mM EDTA, 1 % (v/v) glycerol, pH 8.0 overnight. Aliquotes of 5 μ l were transferred to the assay mixtures, and activity measured using standard assay conditions.

Determination of pH/NaCl-optimum

Assays were done in a volume of 20 μ l as described in standard assay using the PCR generated substrate and NaCl concentration from 0-200 mM with 25 mM intervals, and pH ranging from 9.5-6.5 with 0.5 pH unit intervals. All buffers were supplemented with 100 μ g/ml BSA and 1 mM EDTA. The buffers used were diethanolamine/HCl (9.5-8.5), Tris/HCl (8.5-7.5) and MOPS/NaOH (7.5-6.5). All buffers were pH adjusted at 37°C and used in 25mM concentration in the assay.

Determination of temperature optimum

Assays were done in a volume of 20 μ l as described in standard assay using the PCR generated substrate. The assay mixtures were as described in standard assay conditions and were adjusted to pH 8.0 for all temperatures. The temperature range used was 5°C to 60°C. The activity was measured in a sequential manner with 15 min intervals between each temperature. The enzymes used were diluted in standard dilution buffer (5 mM Tris/HCl, 10 mM NaCl, 1 % (v/v) glycerol, pH 8.0) and placed on ice. Due to the instability of the enzyme sample on ice over a prolonged period, results were corrected with respect to the

stability of the enzymes incubated in dilution buffer on ice, with the formula $N_{(t)} = \text{cpm} / e^{-0.693(t/\lambda)}$, where half-life (λ) of cUNG and rhUNG are 2.0 hours and 2.6 hours respectively.

5

Effect of pH and temperature on stability

pHUNG (0.01 U) was preincubated (in a total volume of 75 μ l) for 10 min at 37° in buffers containing 10 mM buffer, 10 mM NaCl, 1 mM EDTA, 1% glycerol, with pH ranging from 9.5-6.5 with 0.5 pH unit intervals using diethanolamine/HCl (9.5-8.5), Tris/HCl (8.5-7.5), MOPS/NaOH (7.5-6.5) and MES/NaOH (6.5-5.5) as buffer components. Aliquots of 5 μ l were transferred to the assay mixtures and residual activity was measured using standard assay conditions.

15

Temperature UNG (0.01 U) was preincubated (in a total volume of 75 μ l) in 10 mM Tris/HCl, 50 mM NaCl, 1mM EDTA, 1% glycerol, pH 8.0 (adjusted at each temperature). After different time intervals, as indicated in figure legends, 5 μ l aliquots were transferred to the assay mixtures and residual activity was measured using standard assay conditions.

20

Substrate specificity against ss/ds DNA

PCR and Nick-translated substrate was incubated 3 min at 100°C and thereafter rapidly cooled on ice to generate ssDNA. Following denaturation, the ssDNA-substrates were used in standard assay condition with 6.65×10^{-4} U purified cUNG. Enzyme activity was also measured using dsDNA-substrates for both Nick- and PCR-substrate, and used as references.

25

: :

30

Ugi inhibitor- and uracil product inhibition

Activity measurements using PCR-substrate were performed with 6.65×10^{-4} U of purified cUNG. Various concentrations of uracil (0, 1, 2 and 5 mM) or Ugi-inhibitor (1.25×10^3 U to 2.00×10^2 U) were added to the assay mixtures (on ice). Activity was then measured as described under standard assay conditions.

RESULTS

10 Purification of cUNG

Atlantic cod UNG was purified 17,000 fold with a recovery of 2%, as shown in table 1. Despite the high purification factor the enzyme was only partly purified, as determined by SDS-PAGE. Also the yield was low, due to many purification steps, and the concentration of the dilute protein sample before the gel-filtration step.

Molecular weight and pI-determination

The molecular weight was determined by gel filtration to be 25 kD \pm 2, from three separate experiments. The isoelectric point determination was done with an IEF Phast Gel with IEF standards ranging from 4.42 - 9.6. Following IEF, cUNG activity was eluted from the gel fragments and activity measured as described in material and methods. cUNG activity co-eluted with the cytochrome c, standard with an isoelectric point of 9.6, as shown in figure 1. The cytochrome c and cUNG activity were found where the electrode contacted the gel, therefore we can only conclude that the pI is larger than 9.0, which is the highest measurable value using this system.

Substrate specificity

cUNG activity was measured using both ssDNA and dsDNA. A 1.8 and 1.9 fold higher activity for ssDNA than dsDNA was found using Nick- and PCR- substrates, respectively, as shown in table 2. Assay products were analyzed by thin layer chromatography, and the major part of the radioactivity was identified as uracil. However, some radioactivity was also co-localized with the deoxyuridine marker, but this could be due to the partial overlap of the two markers. In addition the purified cUNG did not exhibit any significant hydrolysis of ³H-adenine-labelled DNA, therefore excluding nucleases as responsible for hydrolyzing the DNA.

15 Inhibition studies

Product inhibition by free uracil was examined, and gave more than 50 % inhibition with 1 mM uracil in the assay mixture, as shown in figure 2. Adding 5 mM free uracil to the assay mixture, a 78 % inhibition of the activity was observed. The effect of Ugi on cUNG was measured by adding Ugi to the assay mixture. cUNG was clearly inhibited by Ugi, as shown in figure 3.

pH and NaCl optimum

25 The pH- and sodium chloride optimum was examined by measuring the enzyme-activity at different pHs using NaCl- concentration from 0-200 mM, as shown in figure 4. The enzyme exhibited a broad pH-optimum, with maximal activity between pH 7.0-9.0, and 25-50 mM NaCl. A shift in NaCl optimum was observed, where the optimum NaCl concentration changed from low concentrations at high pH to higher concentrations at low pH. At pH 9.5 cUNG was inhibited by NaCl.

Temperature optimum

The temperature optimum of cUNG was determined to 41°C (figure 5). To compare the activity of cUNG with the mesophilic rhUNG at low temperatures, enzyme activity was measured from 5-60 °C, and the activity at low temperatures compared to their respective optimum temperature (figure 6). The activity profile of these two enzymes showed little difference at 5-15°C. However at temperatures from 20-40°C, a higher relative activity was observed with cUNG than rhUNG, whereas at high temperatures (50-60°C) the opposite was observed.

Stability experiments

The stability of the two UNG enzymes were compared by preincubating the enzymes at different pHs. Atlantic cod UNG was shown to be most stable between pH 7.0-8.5. At pH 5.5 and pH 10.0 it had less than 1 % residual activity. rhUNG was most stable between pH 7.0-9.5. At pH 5.5 3 % residual activity remained, but at pH 10.0, as much as 66% of the activity remained, as shown in figure 7. The temperature stability of the two UNG-enzymes was compared at 4°C, 25°C, 37°C and 50°C. At 50°C, the half-life was determined to be 0.5 min and 8 min for cUNG and rhUNG respectively. At all temperatures examined, rhUNG was more stable than cUNG. Half-lives determined were 20 min (37°C), 60 min (25°C) and 2 h (4°C) for cUNG and 30 min (37°C), 150 min (25°C) and 2.6 h (4°C) for rhUNG, but the largest difference in half-life was found at the highest temperature, as shown in figure 8.

DISCUSSION

Purification and molecular weight

The uracil-DNA glycosylase from Atlantic cod liver (*Gadus morhua*) was purified 17,679 fold using several chromatographic techniques. Still the enzyme was only partly purified, as several other bands were seen on a SDS-PAGE gel. Human nuclear and mitochondrial uracil-DNA glycosylases are shown to be generated by alternate splicing, and have a ORF of 313 and 304 amino acids respectively [49]. The molecular weight of cUNG was determined to 25 kD. This is approximately the same molecular weight as determined for the UNG from human placenta (29kD) and the rhUNG (UNGΔ84) (27kD), which lacked 77 and 84 of the first N-terminal amino acids respectively, as predicted from the mitochondrial ORF [21, 62]. This suggest that the N-terminal signal sequence in the purified cUNG is processed or artificially cleaved during purification or that Atlantic cod UNG does not have a N-terminal signal sequence. During purification we did not see any sign of two different UNGs as previously described during purification of UNG from rat or human sources [18, 23]. But as a vertebrate, one should expect that Atlantic cod possesses both a nuclear and a mitochondrial form of UNG, but so far no effort has been given to reconcile this matter.

The uracil-DNA glycosylase from Atlantic cod was similar to other uracil-DNA glycosylases previously purified and characterized with respect to the high pI [19] and the two-fold preference to ssDNA than dsDNA [19].

Inhibition by Ugi and uracil

The *Bacillus subtilis* bacteriophage PBS2 UDG-inhibitor (Ugi) inhibits UNG by forming a stable complex with UNG at

physiological conditions [63, 64]. Ugi binds to human UNG by inserting a beta-strand into the conserved DNA binding groove [65], and act by mimicking DNA [66]. This indicates that the structure of the substrate binding site of cUNG is similar to other UNGs inhibited by the Ugi-inhibitor. Inhibition with free uracil was in agreement with values previously reported [19].

pH and NaCl Optimum/NaCl

cUNG was shown to have a broad pH optimum from 7.0-9.0, and the activity was strongly affected by NaCl-concentration. The broad optimum activity is previously reported for several other UNGs characterized [23, 31, 40, 47]. Interestingly the NaCl-optimum for cUNG increases as pH decreases. It has previously been demonstrated that UNG functions in a processive manner at low ionic strength, which as NaCl-concentration increases the enzyme switches to a distributive mechanism [14] [15]. However Purmal et al reported the opposite, that UNG acted in a distributive mechanism at low ionic strength. The processive mechanism is a common feature among several DNA interactive proteins (polymerases, repressors, restriction/ modification enzymes, DNA repair enzymes), and the interactions are generally electrostatic in nature [67-69]. In a UV-endonuclease from *Micrococcus luteus* the processive mechanism has also been shown to be pH-dependent [70]. Therefore we suggest that the shift in NaCl-optimum with increasing pH reflects the processive/distributive nature of cUNG. And it could be that the controversy in the previous reports are also due to different buffer components and pH, in addition to the differences already discussed.

The temperature optimum (41°C) was found to be slightly lower than the mesophilic rhUNG (45°C) [62]. The relative activity at temperature from 5-45°C was higher for cUNG

than rhUNG. At temperatures higher than 45°C, rhUNG shows a higher relative activity than cUNG, presumably as a consequence of the low temperature stability of cUNG.

5 Temperature and pH stability

Enzymes characterized from cold-adapted species have been found to be more temperature and pH-labile, proposed due to their flexible structure in order to maintain enzymatic activity at low temperatures [71]. cUNG was found to be both more pH- and temperature labile than the rhUNG, which are known features for other cold-adapted enzymes [71, 72].

A psychrophilic UNG from a marine bacterium has previously been isolated, and was compared to *E.coli* UNG with respect to temperature stability [45]. This procaryotic UNG had a half-life of 2 min at 40°C and 0.5 min at 45°C, compared to 27 and 8 min for the *E.coli* UNG. cUNG was compared to the rhUNG with respect to both temperature and pH stability. At 50°C rhUNG had a half-life of 8 min, compared to 0.5 min for cUNG. At lower temperature the difference in half-life was less, although rhUNG was more stable than cUNG at all temperatures examined. Both enzymes were shown to be labile at low pH, whereas at high pH rhUNG was more stable than cUNG.

In conclusion, the uracil-DNA glycosylase from Atlantic cod was shown to be similar to other uracil-DNA glycosylases previously purified and characterized with respect to molecular weight, high pI, a broad pH-optimum and a two-fold preference to ssDNA than dsDNA. However the cUNG was shown to be more temperature and pH-labile and has a higher relative activity at low temperatures than the mesophilic rhUNG. Take into consideration that UNG is a conserved enzyme among different species, cUNG could be a suitable enzyme for further studies of cold-adaption at the molecular level.

Isolation of the uracil-DNA glycosylase gene from *Gadus morhua*

5 MATERIALS

SuperScript™ II RNase H⁻ Reverse Transcriptase (Gibco BRL), Packagene® Lambda DNA packaging system was purchased from Promega (Madison, WI), Deoxy[5-³H]uridine 5'-triphosphate
10 (17.0 Ci/mmol) was purchased from Amersham (England), expression vector pTrc99A was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden), restriction enzymes were purchased from New England Biolabs (Beverly, MA), SMART™ PCR cDNA Library Construction kit and Marathon™
15 cDNA Amplification Kit were purchased from Clontech (Palo Alto, CA). *Escherichia coli* NR8052 [Δ (*pro-lac*), *thi*-, *ara*, *trpE9777*, *ung1*] [Kunkel, 1985 #197][Varshney, 1989 #196] and purified recombinant human UNG (UNG Δ 84) [Slupphaug, 1995 #47] was provided by Dr. Hans E. Krokan, Institute for
20 cancer research and Molecular Biology, Norwegian University of Science and Technology.

METHODS

Isolation of mRNA

25 mRNA was isolated from 250 mg cod liver using Oligotex direct mRNA Midi kit (Qiagen), following the instructions
: : in manufacturers protocol.

Preparation of cDNA

30 cDNA was made from 250 ng of the isolated poly A⁺ RNA using SMART™ PCR cDNA Library Construction kit (Clontech) according to the protocol recommended by the manufacturer. In brief, 1st strand cDNA was made by combining 250 ng poly

A+ RNA with 10 pmol SMART oligonucleotide (5'-TACGGCTGCGAGAAGACGACAGAAGGG-3') and 10 pmol CDS/3' PCR primer (Oligo(dT)30 N -1 N (N = A, G, C, or T; N -1 = A, G, or C)) in a final volume of 5 µl, and incubated at 72°C for 2 min and then placed directly on ice for 2 min to denature the RNA. Then enzyme and buffer were added to the reaction mixture to a final volume of 10 µl, consisting of 50 mM Tris/HCl, pH 8.3, 6 mM MgCl₂, 75 mM KCl, 2 mM DTT, 1 mM dATP, dCTP, dGTP and dTTP respectively and 200 U SuperScript™ II reverse transcriptase (Gibco BRL), and then incubated at 42°C for 1 h. Synthesis of 2nd strand was done by PCR in a final volume of 100 µl, containing 2 µl of the 1st strand reaction as template, 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of dATP, dCTP, dGTP and dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 0.2 µM 5'-PCR primer (5'-TACGGCTGCGAGAAGACGACAGAA-3') and CDS/3'-PCR primer respectively.

PCR amplification was done in a GeneAmp 9700 thermocycler (Perkin Elmer), by 95°C for 1 min followed by 16 cycles of 95°C for 15 sec and 68°C for 5 min.

ds cDNA polishing To 50 µl of the amplified ds cDNA, 40 µg proteinase K was added and incubated at 45°C for 1 h. Proteinase K was inactivated by incubating the mixture at 90°C for 8 min. To blunt end the ds cDNA, 15 U of T4 DNA polymerase was added and incubated at 16°C for 30 min and 72°C for 10 min. Finally the ds cDNA was ethanol precipitated and resuspended in 10 µl H₂O. All tubes were kept on ice if not otherwise stated.

Generation of a 300 bp fragment of the cUNG-gene

Degenerated oligonucleotide primers were designed from two conserved regions (GQDPYH and VFLLWG) from known UNG- amino acid sequences. Codon usage for Atlantic cod were also

considered when designing the primers. The UNG fragment was generated by PCR with cod liver cDNA as template in a final volume of 50 μ l, containing 10 mM Tris/HCl pH 9.0 (25°C), 50 mM KCl, 0.1% Triton X-100, 10 ng cDNA, 0.2 mM dATP, dCTP, dGTP and dTTP respectively, 2.0 μ M upstream primer (5'-GGH-CAR-GAY-CCC-TAY-CA-3') and downstream primer (5'-DCC-CCA-SAG-SAG-RAA-VAC-3')¹ respectively and 2.5 U Taq-polymerase (Promega). PCR was carried out by 94°C for 4 min, 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final extension step of 72°C for 5 min.

DNA sequencing

DNA sequencing was done with the Amersham Pharmacia Biotech Thermo Sequenace Cy5 Dye Terminator Kit, ALFexpress™ DNA sequencer and ALFwin Sequence Analyzer version 2.10. Gels were made with Reprogel™ Long Read and Reproset UV-polymerizer. All items were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).

RACE procedure

Ligation of adaptors to cDNA was done as described in the protocol from the manufacturer. In brief, RACE-adaptors were ligated to cDNA in a total volume of 10 μ l containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 0.75 μ g cDNA, 2 μ M Marathon cDNA adaptor (Clontech), 400 U T4 DNA ligase. The reaction was incubated at 16°C for 16 h, and 5 min at 70°C to inactivate the ligase. Before RACE, the adaptor ligated cDNA was diluted 50 times in TE-buffer and denatured at 100°C for 2 min and placed directly on ice.

¹ Nucleotide symbols:

A=Adenine; C=Cytosine; G=Guanine; T=Thymine; D= A+G+T; R=A+G; S=C+G; V=A+C+ G; Y=C+T

The sequence deduced from the 300 bp fragment of the UNG-gene was used to design two primers for both 3'- and 5'-rapid amplification of cDNA ends (RACE), with a small overlap region between the two fragments generated. Both

5 3'- and 5'-RACE reactions were done in a volume of 50 μ l with 1 μ l of diluted cDNA with RACE-adaptors as template, 0.2 μ M internal 3'- (5'-TGTACCGACATTGATGGCTTCAAGCAT-3') or 5' (5'-CCCATCCGCTTAGATCTCCATGTCCAG-3') RACE primers, respectively, 0.2 μ M AP1-primer (supplied by

10 manufacturer) (5'-CCATCCTAATACGACTCACTATAGGGC-3'), 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 μ g/ml BSA, 0.2 mM of each dATP, dCTP, dGTP and dTTP and 1U Advantage cDNA Polymerase Mix (Clontech). Amplification was done in a GeneAmp 9700 thermocycler

15 (Perkin Elmer), 94°C for 30 sec followed by 5 cycles of 94°C for 5 sec and 72°C for 3 min, 5 cycles of 94°C for 5 sec and 70°C for 3 min, and 20 cycles of 94°C for 5 sec and 68°C for 3 min.

20 (Individual bands were purified from an agarose gel, and used as template in a new PCR-reaction with the same conditions as above to generate more DNA.)

Isolation of two different UNG genes

25 Both RACE-fragments generated were sequenced using their respective internal RACE-primers.

Examining the sequence of the 5'-RACE-fragment indicated a double sequence, difficult to read, near the 5'-end of the

: : fragment. However at the end of the fragment only one

30 sequence appeared, due to a long UTR in one of the UNG-sequences but not the other. A new primer complementary to this 5'-end was designed (5'-ATGGAATTGATTGAGATTGGCGCCTTTGG-3') and a new PCR-reaction was carried out with this, and the 5'-RACE internal primer, with the 5'-RACE fragment as

35 template. The PCR was carried out in a final volume of 50 μ l with 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM

Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of dATP, dCTP, dGTP and dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 10 ng cDNA as template and 0.2 µM upstream and downstream primers respectively. Amplification was done in
 5 a GeneAmp 9700 thermocycler (Perkin Elmer), 94°C for 1 min. followed by 30 cycles of 94°C for 30 sec, 60°C for 1 min and 72°C for 1 min.

The fragment was sequenced using the internal RACE-primer,
 10 and the sequence was subtracted from the double sequence region described above. A primer complementary to the 5p-end of the underlying sequence was designed (consisting of both nucleotides from the SMART-sequence and the remaining UNG-sequence), and a PCR-reaction with this and the
 15 internal 5'-RACE-primer was carried out. The new fragment was sequenced as described above. From the two different UNG-sequences in the 5'-RACE-fragment, two final primers (UNG1 and UNG2) were made to isolate the full length UNG1 and UNG2, respectively, using cDNA as template and the same
 20 PCR-conditions as described above.

Construction of expression vectors

The catalytic domain of the UNG-gene was cloned in the expression vector pTrc99A, containing a strong trc promoter
 25 upstream of a multiple cloning site [Amann, 1988 #195]. Several different constructs were made by PCR-amplifying the gene using cDNA as template with upstream and downstream primers containing EcoRI and SalI restriction
 : : sites respectively. DNA-fragments were purified, digested
 30 with EcoRI and SalI and ligated into the pTrc99A expression vector. In brief, PCR-fragments with restriction sites were generated in a PCR-reaction (50 µl) containing 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of dATP, dCTP, dGTP and
 35 dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 10 ng cDNA as template and 0.2 µM upstream and

downstream primers respectively. Amplification was done in a GeneAmp 9700 thermocycler (Perkin Elmer), 94°C for 1 min followed by 30 cycles of 94°C for 30 sec, 60°C for 1 min and 72°C for 2 min, and a final extension step of 72°C for 5 min. Individual bands were purified from agarose gel, and used as template in a new PCR-reaction, with the same conditions as described above, to generate more DNA. DNA was purified using Quiaquick PCR purification kit (Millipore) as described by manufacturer, and eluted in TE-buffer, pH 8.0. Restriction enzyme digestion was done in a final volume of 30 µl containing 1 µg insert DNA or 0.25 µg pTrc99A vector, 6 mM Tris/HCl, pH 7.9, 6 mM MgCl₂, 150 mM NaCl, 1 mM DTT (BufferD, Promega) and 3U of EcoRI and SalI. The mixtures were incubated at 37°C for 3 h, followed by two times phenol/chloroform extraction, ethanol precipitation and resuspended in 5 µl H₂O. Ligations were performed in a total volume of 10 µl containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 100 U T4 DNA ligase, 250 ng vector DNA and 1 µg insert DNA, and incubated at 16°C for 16 h.

Competent E. coli JM105 (200 µl) was transformed with ligation mixes and grown on LB+ plates containing 100 µg/ml ampicillin at 37°C. Plasmid DNA was reisolated from positive clones and transformed in E. coli NR8052 used for expression of recombinant UNG.

Small scale expression of uracil-DNA glycosylase

Optimization of expression were done in 11 baffled erlenmeyer flasks with 100 ml LB+ medium with 100 µg/ml ampicillin, inoculated with 5 ml of preculture. Cells were induced with 1 mM of IPTG at OD₆₀₀ = 2.0, and induced at various length as indicated in figure legends. Expression was examined using various temperatures (20°C, 25°C, 30°C and 37°C).

The conditions above were also used to induce expression at various IPTG-concentrations (1 mM, 0.5 mM, 0.1 mM and 0.01mM).

5 Fermentation conditions

Fermentation was done in a 10 l Chemap CF 3000 fermentor (Switzerland). A 200 ml preculture of *E.coli* NR8052 with the pTrc99A oΔ84 construct was inoculated to 7 l of LB-medium supplemented with 20 mM glucose and 100 µg/ml
10 ampicillin. Cells were grown to an OD600 of 2.0 and induced for 8 h with 1 mM IPTG. Additional glucose (3 x 50 ml of 20% glucose (W/v)) was supplemented during the fermentation to avoid glucose starvation. Cells were harvested and centrifuged at 10.000 g for 10 minutes. The cell paste was
15 frozen at -70°C.

Purification of recombinant cod UNG

Crude extract

From the fermentation, 4 l of the *E. coli* NR8052 cells (68
20 g wet weight) were resuspended in 400 ml of extraction buffer (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1 % glycerol, 1 mM DTT, 1 mM PMSF pH 8,0). The cells were disrupted by subjecting them five times through the Nebulizer using 100 psi of nitrogen. The extract was
25 centrifuged 25.000 g for 10 min, and the supernatant removed. The pellet was resuspended in 100 ml of buffer A, and recentrifuged as described above. The supernatants were combined and filtrated through glasswool (460 ml).

30 Protamine sulphate

To the crude extract (460 ml), 60 ml of 2 % protamine sulphate in buffer A (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1 % glycerol, pH 8.0) was added and incubated at 4°C

for 5 min with stirring. The solution was centrifuged at 25.000 g for 10 min, and the supernatant was removed, 510 ml (fraction 1).

5 Q/S-sepharose

The protamine sulphate fraction was applied on a Q-sepharose column (5.0/10) coupled with a S-sepharose column (2.6/10), both equilibrated in buffer A, using a flow rate of 10 ml/min. Then the columns were washed with 750 ml buffer A, and the Q-sepharose column was then removed. The S-sepharose column was washed with an additional 550 ml buffer A + 60 mM NaCl, and a gradient of 60 to 400 mM NaCl in buffer A was applied to elute the column, using a flow rate of 5 ml/min. Fractions of 10 ml were collected, and fractions containing UNG-activity were pooled (fraction 2, 110 ml).

Blue sepharose FF

Fraction 2 was diluted two times in buffer A, and directly applied to a blue sepharose column (1.6/5.0), with a flow rate of 4 ml/min. The column was then washed with 30 ml of buffer A and 60 ml of buffer A + 110 mM NaCl, and eluted with 60 ml buffer A + 0.7 M NaCl. UNG containing fractions were pooled (fraction 3, 24 ml).

25

Superdex 75

Fraction 3 was concentrated to 3 ml using a Ultrafree 15 unit, (Millipore) and applied to the superdex 75 column (2.6/60) equilibrated in buffer A + 0.15 M NaCl. A flow rate of 2 ml/min was used, and fractions of 5 ml were collected. Fractions containing UNG-activity were pooled (fraction 4, 30 ml).

mangler

Source 150

RESULTSSequence of cUNG1 and cUNG2

mangle cUNG1/cUNG2

Expression

- Expression of rcUNG by the pTrc99A-oΔ84 construct in 7L scale fermentation yielded a total of 413,480 Units of rcUNG contained in the crude extract.

Purification of recombinant cod UNG

- Purification of recombinant cUNG (rcUNG) is summarized in table 1. From a 7 l fermentation, 10 mg of recombinant UNG was purified with a 70% yield from the crude extract and the specific activity of the enzyme was determined to 30,000 U/mg using the nick-generated substrate.

- Example: Carry over prevention

Method

- As a contaminant, 0.5 ng of uracil-containing template DNA (761 bp fragment generated from cationic trypsinogen from Atlantic salmon (*Salmo salar*) [Male, 1995 #153]) was added to the PCR-mix in a final volume of 50 µl, containing 10 mM Tris/HCl pH 9.0 (25°C), 50 mM KCl, 0.1% Triton X-100, 10 ng cDNA, 0.2 mM dATP, dCTP, dGTP and dTTP respectively, 2.0 µM upstream- (OP5) and downstream primer (NP2) respectively and 1.0 U Taq-polymerase (Promega). UNG (4×10^{-3} or 1.7×10^{-2} U) was added to the PCR-mix and incubated at RT for 10 minutes.

- As negative controls, one PCR reaction mixture contained template with thymidine replacing uracil, and in one mixture water replaced UNG. Also, as a positive control 1.7×10^{-3} U UNG from *E. coli* was used.

Then PCR was carried out by 94°C for 4 min, 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min. After the PCR the products were analyzed by agarose gel

5 electrophoresis.

PCR primer sequences:

OP5:

5' -TCTCTCGAGAAAAGAGAGGCTGAAGCTCCCATTGACGATGAGGATGA-3'

10

NP2:

5' -GTAGAATTCGGATCCATGTCTCCTCCAGTCTAGAT-3'

Result

15 The result of the experiment according to the example is shown in fig. 9. The uracil-containing templates were degraded by UNG in all PCR reactions while the reactions either without UNG or with thymine-containing templates yielded the expected PCR product. The results in fig. 9 are
20 shown as a figure of an agarose gel.

Table 1: Purification of Atlantic cod liver uracil-DNA glycosylase (cUNG).

Step	Volume (ml)	Activity _a (U/ml)	Total activity (U)	Protein conc (mg/ml) _b	Total protein (mg)	Specific activity (U/mg)	Yield (%)	Purification Fold
Crude extract	2000	0,086	172	4	8000	0,021	100	1
Q-Sepharose FF	2340	0,073	170	1,66	3884	0,044	99	2
S-Sepharose FF	55	1,796	98,8	0,155	8,53	11,6	58	540
Heparin Sepharose	20	2,775	55,5	0,081	1,62	34,3	32	1597
Poly-U Sepharose	70	0,446	31,2	ND _c	ND	ND	18	ND
Superdex75	3	1,138	3,41	0,003	0,009	379	2	17679

a) Enzyme activity was measured as described under standard assay in material and methods using nick-substrate.

5 b) Protein concentration was determined as described in material and methods.

c) Protein concentration was too low to determine.

Table 2: Substrate specificity ssDNA versus dsDNA.

Substrate	cpm	% activity	Fold
dsNick	586	54	1,0
ssNick	1078	100	1,8
dsPCR	1158	52	1,0
ssPCR	2214	100	1,9

10

Figure 1 shows pI determination of Atlantic cod UNG (cUNG). Following the isoelectric focusing using Phast Gel IEF 3-9, the gel was cut in pieces of 2 mm. Each piece was transferred to an eppendorf tube and incubated overnight at 15 4 °C. Activity was then measured as described in material and methods.

20

Figure 2 shows product inhibition of cUNG with free uracil. Different concentrations of uracil were added to the assay mixture and the assay performed as described in material and methods.

Figure 3 shows inhibition of cUNG with the *Bacillus subtilis* bacteriophage uracil-DNA glycosylase inhibitor (Ugi). 6.65×10^{-4} U of cUNG was incubated with 1.25×10^3 U to 2.00×10^2 U of Ugi using standard assay conditions, as described in material and methods. One Unit of Ugi inhibit one Unit of UNG-activity, where the UNG-activity is defined as releasing 60 pmol of uracil per min at 37°C.

10 Figure 4 shows pH and NaCl optimum of cUNG. Activity of cUNG was measured with variable sodium chloride concentrations in different pH-series, as described in material and methods. The percent UNG activity is set relative to the highest value measured, pH 7.5 with 50 mM
15 NaCl.

Figure 5 shows temperature optimum of cUNG. Due to prolonged incubation of the enzyme sample on ice during the experiment, activity is corrected with respect to the
20 stability of the enzyme, as described in material and methods.

Figure 6 shows Temperature profile of cUNG (σ) and rhUNG (ν). Enzyme activity was measured as described in material
25 and methods. The percent UNG activity is set relative to the highest value for cUNG (45°C) and rhUNG (50°C) respectively. Due to prolonged incubation of the enzyme samples on ice during the experiment, activity is corrected with respect to the stability of the enzymes, as described
: 30 in material and methods.

Figure 7 shows pH stability of Atlantic cod UNG (cUNG) and recombinant human UNG (rhUNG). In the different pH-buffers, 1 U of cUNG (σ) or rhUNG (ν) were incubated for 10 minutes
35 at 37°C. Then 5 μ l aliquotes were transferred to the assay mixture, and residual activity was measured using standard assay conditions as described in materials and methods. One

hundred percent activity was measured directly from a sample diluted at pH 8.0 without any incubation step.

Figure 8 shows temperature stability of Atlantic cod UNG (cUNG) (σ) and recombinant human UNG (rhUNG) (ν).

Enzyme (1 U) were incubated at 50°C, 37°C, 25°C and 4°C, and 5 μ aliquotes were transferred to the assay mixture after different time intervals, and standard assays were performed as described in material and methods. Half-lives were determined to 0.5 min (50°C), 20 min (37°C), 60 min (25°C) and 2 h (4°C) for cUNG and 8 min (50°C), 30 min (37°C), 150 min (25°C) and 2.6 h (4°C) for rhUNG.

Figure 9 shows agarose gel showing PCR products from carry-over prevention test using recombinant Cod UNG (rcUNG). Lane descriptions: lanes 1 and 8: DNA ladder; lane 2: T-containing template, no UNG; lane 3: T-containing template, 1.7×10^{-3} U rcUNG; lane 4: U-containing template, 4×10^{-4} U rcUNG; lane 5: U-containing template, 1.7×10^{-3} U rcUNG; lane 6: U-containing template, 4×10^{-4} U *E. coli* UNG; lane 7: U-containing template, no UNG.

REFERENCES

1. Lindahl, T., *An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues*. Proc Natl Acad Sci U S A, 1974. 71(9): p. 3649-53.
2. Lindahl, T., *DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision-repair*. Prog Nucleic Acid Res Mol Biol, 1979. 22: p. 135-92.
3. Kubota, Y., et al., *Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein*. Embo J, 1996. 15(23): p. 6662-70.

4. Nicholl, I.D., K. Nealon, and M.K. Kenny,
Reconstitution of human base excision repair with
purified proteins. *Biochemistry*, 1997. 36(24): p.
7557-66.
5. Parikh, S.S., C.D. Mol, and J.A. Tainer, Base excision
repair enzyme family portrait: integrating the
structure and chemistry of an entire DNA repair
pathway. *Structure*, 1997. 5(12): p. 1543-50.
6. Slupphaug, G., et al., Cell cycle regulation and in
vitro hybrid arrest analysis of the major human
uracil-DNA glycosylase. *Nucleic Acids Res*, 1991.
19(19): p. 5131-7.
7. Muller, S.J. and S. Caradonna, Isolation and
characterization of a human cDNA encoding uracil-DNA
glycosylase. *Biochim Biophys Acta*, 1991. 1088(2): p.
197-207.
8. Muller Weeks, S.J. and S. Caradonna, Specific
association of cyclin-like uracil-DNA glycosylase with
the proliferating cell nuclear antigen. *Exp Cell Res*,
1996. 226(2): p. 346-55.
9. Haushalter, K.A., et al., Identification of a new
uracil-DNA glycosylase family by expression cloning
using synthetic inhibitors. *Curr Biol*, 1999. 9(4): p.
174-85.
10. Gallinari, P. and J. Jiricny, A new class of uracil-
DNA glycosylases related to human thymine-DNA
glycosylase. *Nature*, 1996. 383(6602): p. 735-8.
11. Barrett, T.E., et al., Crystal structure of a G:T/U
mismatch-specific DNA glycosylase: mismatch
recognition by complementary-strand interactions.
Cell, 1998. 92(1): p. 117-29.
12. Sandigursky, M. and W.A. Franklin, Thermostable
uracil-DNA glycosylase from *Thermotoga maritima* a
member of a novel class of DNA repair enzymes. *Curr*
Biol, 1999. 9(10): p. 531-4.
13. Krokan, H.E., R. Standal, and G. Slupphaug, DNA
glycosylases in the base excision repair of DNA.
Biochem J, 1997. 325(Pt 1): p. 1-16.

14. Higley, M. and R.S. Lloyd, *Processivity of uracil DNA glycosylase*. *Mutat Res*, 1993. 294(2): p. 109-16.
15. Bennett, S.E., R.J. Sanderson, and D.W. Mosbaugh, *Processivity of Escherichia coli and rat liver mitochondrial uracil-DNA glycosylase is affected by NaCl concentration*. *Biochemistry*, 1995. 34(18): p. 6109-19.
16. Purmal, A.A., et al., *Uracil DNA N-glycosylase distributively interacts with duplex polynucleotides containing repeating units of either TGGCCAAGCU or TGGCCAAGCTTGGCCAAGCU*. *J Biol Chem*, 1994. 269(35): p. 22046-53.
17. Colson, P. and W.G. Verly, *Intracellular localization of rat-liver uracil-DNA glycosylase. Purification and properties of the chromatin enzyme*. *Eur J Biochem*, 1983. 134(3): p. 415-20.
18. Domena, J.D. and D.W. Mosbaugh, *Purification of nuclear and mitochondrial uracil-DNA glycosylase from rat liver. Identification of two distinct subcellular forms*. *Biochemistry*, 1985. 24(25): p. 7320-8.
19. Domena, J.D., et al., *Purification and properties of mitochondrial uracil-DNA glycosylase from rat liver*. *Biochemistry*, 1988. 27(18): p. 6742-51.
20. Seal, G., P. Arenaz, and M.A. Sirover, *Purification and properties of the human placental uracil DNA glycosylase*. *Biochim Biophys Acta*, 1987. 925(2): p. 226-33.
21. Wittwer, C.U., G. Bauw, and H.E. Krokan, *Purification and determination of the NH₂-terminal amino acid sequence of uracil-DNA glycosylase from human placenta*. *Biochemistry*, 1989. 28(2): p. 780-4.
22. Krokan, H. and C.U. Wittwer, *Uracil DNA-glycosylase from HeLa cells: general properties, substrate specificity and effect of uracil analogs*. *Nucleic Acids Res*, 1981. 9(11): p. 2599-613.
23. Wittwer, C.U. and H. Krokan, *Uracil-DNA glycosylase in HeLa S3 cells: interconvertibility of 50 and 20 kDa forms and similarity of the nuclear and mitochondrial*

form of the enzyme. *Biochim Biophys Acta*, 1985.
832(3): p. 308-18.

24. Myrnes, B. and C.U. Wittwer, *Purification of the human O6-methylguanine-DNA methyltransferase and uracil-DNA glycosylase, the latter to apparent homogeneity*. *Eur J Biochem*, 1988. 173(2): p. 383-7.
25. Caradonna, S., et al., *Affinity purification and comparative analysis of two distinct human uracil-DNA glycosylases*. *Exp Cell Res*, 1996. 222(2): p. 345-59.
- 10 26. Muller-Weeks, S., B. Mastran, and S. Caradonna, *The nuclear isoform of the highly conserved human uracil-DNA glycosylase is an Mr 36,000 phosphoprotein*. *J Biol Chem*, 1998. 273(34): p. 21909-17.
- 15 27. Seal, G., R.J. Tallarida, and M.A. Sirover, *Purification and properties of the uracil DNA glycosylase from Bloom's syndrome*. *Biochim Biophys Acta*, 1991. 1097(4): p. 299-308.
- 20 28. Caradonna, S.J. and Y.C. Cheng, *Uracil DNA-glycosylase. Purification and properties of this enzyme isolated from blast cells of acute myelocytic leukemia patients*. *J Biol Chem*, 1980. 255(6): p. 2293-300.
- 25 29. Talpaert-Borle, M., L. Clerici, and F. Campagnari, *Isolation and characterization of a uracil-DNA glycosylase from calf thymus*. *J Biol Chem*, 1979. 254(14): p. 6387-91.
- 30 30. Talpaert-Borle, M., F. Campagnari, and D.M. Creissen, *Properties of purified uracil-DNA glycosylase from calf thymus. An in vitro study using synthetic DNA-like substrates*. *J Biol Chem*, 1982. 257(3): p. 1208-14.
- 35 31. Guyer, R.B., J.M. Nonnemaker, and R.A. Deering, *Uracil-DNA glycosylase activity from Dictyostelium discoideum*. *Biochim Biophys Acta*, 1986. 868(4): p. 262-4.
32. Crosby, B., et al., *Purification and characterization of a uracil-DNA glycosylase from the yeast*.


- Saccharomyces cerevisiae*. Nucleic Acids Res, 1981. 9(21): p. 5797-809.
33. Blaisdell, P. and H. Warner, Partial purification and characterization of a uracil-DNA glycosylase from wheat germ. J Biol Chem, 1983. 258(3): p. 1603-9.
 34. Talpaert-Borle, M. and M. Liuzzi, Base-excision repair in carrot cells. Partial purification and characterization of uracil-DNA glycosylase and apurinic/apyrimidinic endodeoxyribonuclease. Eur J Biochem, 1982. 124(3): p. 435-40.
 35. Birch, D.J. and A.G. McLennan, Uracil-DNA glycosylase in developing embryos of the brine shrimp (*Artemia salina*). Biochem Soc Trans, 1980. 8(6): p. 730-1.
 36. Lindahl, T., et al., DNA N-glycosidases: properties of uracil-DNA glycosidase from *Escherichia coli*. J Biol Chem, 1977. 252(10): p. 3286-94.
 37. Cone, R., et al., Partial purification and characterization of a uracil DNA N-glycosidase from *Bacillus subtilis*. Biochemistry, 1977. 16(14): p. 3194-201.
 38. Williams, M.V. and J.D. Pollack, A mollicute (mycoplasma) DNA repair enzyme: purification and characterization of uracil-DNA glycosylase. J Bacteriol, 1990. 172(6): p. 2979-85.
 39. Kaboev, O.K., et al., Uracil-DNA glycosylase from *Bacillus stearothermophilus*. FEBS Lett, 1981. 132(2): p. 337-40.
 40. Purnapatre, K. and U. Varshney, Uracil DNA glycosylase from *Mycobacterium smegmatis* and its distinct biochemical properties. Eur J Biochem, 1998. 256(3): p. 580-8.
 41. Kaboev, O.K., L.A. Luchkina, and T.I. Kuziakina, Uracil-DNA glycosylase of thermophilic *Thermothrix thiopara*. J Bacteriol, 1985. 164(1): p. 421-4.
 42. Masters, C.I., B.E. Moseley, and K.W. Minton, AP endonuclease and uracil DNA glycosylase activities in *Deinococcus radiodurans*. Mutat Res, 1991. 254(3): p. 263-72.

43. Koulis, A., et al., Uracil-DNA glycosylase activities in hyperthermophilic micro-organisms. FEMS Microbiol Lett, 1996. 143(2-3): p. 267-71.
44. Leblanc, J.P., et al., Uracil-DNA glycosylase.
5 Purification and properties of uracil-DNA glycosylase from *Micrococcus luteus*. J Biol Chem, 1982. 257(7): p. 3477-83.
45. Sobek, H., et al., Heat-labile uracil-DNA glycosylase: purification and characterization. FEBS Lett, 1996.
10 388(1): p. 1-4.
46. Focher, F., et al., Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives. Biochem J, 1993. 292(Pt 3): p. 883-9.
47. Winters, T.A. and M.V. Williams, Purification and characterization of the herpes simplex virus type 2-encoded uracil-DNA glycosylase. Virology, 1993.
15 195(2): p. 315-26.
48. Slupphaug, G., et al., Nuclear and mitochondrial forms of human uracil-DNA glycosylase are encoded by the
20 same gene. Nucleic Acids Res, 1993. 21(11): p. 2579-84.
49. Nilsen, H., et al., Nuclear and mitochondrial uracil-DNA glycosylases are generated by alternative splicing and transcription from different positions in the UNG
25 gene. Nucleic Acids Res, 1997. 25(4): p. 750-5.
50. Bharati, S., et al., Human mitochondrial uracil-DNA glycosylase preform (UNG1) is processed to two forms one of which is resistant to inhibition by AP sites.
: 30 Nucleic Acids Res, 1998. 26(21): p. 4953-9.
51. Haug, T., et al., Regulation of expression of nuclear and mitochondrial forms of human uracil-DNA glycosylase. Nucleic Acids Res, 1998. 26(6): p. 1449-57.
52. Otterlei, M., et al., Nuclear and mitochondrial splice forms of human uracil-DNA glycosylase contain a complex nuclear localisation signal and a strong classical mitochondrial localisation signal,
35

- respectively. *Nucleic Acids Res*, 1998. 26(20): p. 4611-7.
53. Mol, C.D., et al., Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis [see comments]. *Cell*, 1995. 80(6): p. 869-78.
 54. Savva, R., et al., The structural basis of specific base-excision repair by uracil-DNA glycosylase. *Nature*, 1995. 373(6514): p. 487-93.
 - 10 55. Ravishankar, R., et al., X-ray analysis of a complex of *Escherichia coli* uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. *Nucleic Acids Res*, 1998. 26(21): p. 4880-7.
 - 15 56. Slupphaug, G., et al., A nucleotide-flipping mechanism from the structure of human uracil-DNA glycosylase bound to DNA [see comments]. *Nature*, 1996. 384(6604): p. 87-92.
 - 20 57. Parikh, S.S., et al., Base excision repair initiation revealed by crystal structures and binding kinetics of human uracil-DNA glycosylase with DNA. *Embo J*, 1998. 17(17): p. 5214-26.
 - 25 58. Feller, G. and C. Gerday, Psychrophilic enzymes: molecular basis of cold adaptation. *Cell Mol Life Sci*, 1997. 53(10): p. 830-41.
 59. Male, R., et al., Molecular cloning and characterization of anionic and cationic variants of trypsin from Atlantic salmon. *Eur J Biochem*, 1995. 232(2): p. 677-85.
 - 30 60. Wang, K.T. and I.S. Wang, Polyamide-layer chromatography of nucleic acid bases and nucleosides. *Biochim Biophys Acta*, 1967. 142(1): p. 280-1.
 - 35 61. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*, 1976. 72: p. 248-54.
 62. Slupphaug, G., et al., Properties of a recombinant human uracil-DNA glycosylase from the UNG gene and

- evidence that *UNG* encodes the major uracil-DNA glycosylase. *Biochemistry*, 1995. 34(1): p. 128-38.
63. Bennett, S.E., M.I. Schimerlik, and D.W. Mosbaugh, *Kinetics of the uracil-DNA glycosylase/inhibitor protein association. Ung interaction with Ugi, nucleic acids, and uracil compounds.* *J Biol Chem*, 1993. 268(36): p. 26879-85.
 64. Karran, P., R. Cone, and E.C. Friedberg, *Specificity of the bacteriophage PBS2 induced inhibitor of uracil-DNA glycosylase.* *Biochemistry*, 1981. 20(21): p. 6092-6.
 65. Mol, C.D., et al., *Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA.* *Cell*, 1995. 82(5): p. 701-8.
 66. Savva, R. and L.H. Pearl, *Nucleotide mimicry in the crystal structure of the uracil-DNA glycosylase-uracil glycosylase inhibitor protein complex.* *Nat Struct Biol*, 1995. 2(9): p. 752-7.
 67. Lohman, T.M., *Kinetics of protein-nucleic acid interactions: use of salt effects to probe mechanisms of interaction.* *CRC Crit Rev Biochem*, 1986. 19(3): p. 191-245.
 68. von-Hippel, P.H. and O.G. Berg, *Facilitated target location in biological systems.* *J Biol Chem*, 1989. 264(2): p. 675-8.
 69. Dodson, M.L., M.L. Michaels, and R.S. Lloyd, *Unified catalytic mechanism for DNA glycosylases.* *J Biol Chem*, 1994. 269(52): p. 32709-12.
 70. Hamilton, R.W. and R.S. Lloyd, *Modulation of the DNA scanning activity of the *Micrococcus luteus* UV endonuclease.* *J Biol Chem*, 1989. 264(29): p. 17422-7.
 71. Outzen, H., et al., *Temperature and pH sensitivity of trypsins from Atlantic salmon (*Salmo salar*) in comparison with bovine and porcine trypsin.* *Comp Biochem Physiol B Biochem Mol Biol*, 1996. 115(1): p. 33-45.
 72. Berglund, G.I., et al., *Purification and characterization of pancreatic elastase from North*

Atlantic salmon (Salmo salar). Mol Mar Biol
Biotechnol, 1998. 7(2): p. 105-14



C l a i m s

1. Enzyme,
c h a r a c t e r i z e d i n that it has UDG activity
and is completely deactivated when heated above 60°C.
- 5 2. Enzyme according to claim 1,
c h a r a c t e r i z e d i n that it has an amino acid
sequence as shown in fig. 1 or a functional part thereof.
- 10 3. Enzyme according to claim 1 or 2,
c h a r a c t e r i z e d i n that it is derived from
an organism adapted to a cold environment.
- 15 4. Enzyme according to any of the preceeding claims,
c h a r a c t e r i z e d i n that it is derived from
Atlantic cod (*Gadus morhua*).
- 20 5. Enzyme accordig to any of the preceding claims,
c h a r a c t e r i z e d i n that it includes a
traceable label.
- 25 6. DNA sequence,
c h a r a c t e r i z e d i n that it codes for the
enzyme according to any of the claims 1 - 5.
7. DNA sequence,
c h a r a c t e r i z e d i n that it comprises the
nucleotide sequence given in SEQ ID No. 1.
- 30 8. DNA sequence according to claim 6 or 7,
c h a r a c t e r i z e d i n that it includes a
promoter.
- 35 9. DNA sequence according to claim 6, 7 or 8,
c h a r a c t e r i z e d i n that it is contained in
an expression vector, e.g. a plasmid, a cosmid or a virus.

10. DNA sequence according to any of the claims 6 - 9,
c h a r a c t e r i z e d i n that it includes a
traceable label.

5

11. Microorganism,
c h a r a c t e r i z e d i n that it includes a DNA
sequence accordig to any of the claims 6 - 10.

10 12. Microorganism according to claim 11,
c h a r a c t e r i z e d i n that it is a mammalian
cell or a bacterium.

13. Microorganism according to claim 11 or 12,
15 c h a r a c t e r i z e d i n that it is an *E. coli*
strain.

14. Use of an enzyme according to any of the claims 1 - 5
in monitoring an/or controlling a reaction system
20 multiplying DNA sequences, e.g. PCR or LCR.

15. Use of an enzyme according to any of the claims 1 - 5
in carry-over prevention procedures.




A b s t r a c t

It is disclosed a novel enzyme present in cod liver, a DNA sequence encoding the enzyme or operative parts thereof, a novel recombinant DNA comprising the gene or the operative parts thereof, a method of preparing the enzyme from cod liver and from bacteria carrying the gene, the bacteria carrying the gene per se, and the use of the protein in monitoring and/or controlling PCR or related reaction systems.



1c

12. januar 2000
TG/eah
O.nr. 134642



ANSØKER:
BIOTEC ASA
Strandgt. 3
N-9008 Tromsø, Norge

OPPFINNERE:
Opplyses senere

TITTEL:
Varmelabil uracil-DNA-glykosylase samt anvendelse
derav.

Cod Uracil-DNA Glycosylase, Gene coding therefore,
Recombinant DNA Containing said Gene or Operative Parts
thereof, a Method for preparing said Protein and the use of
said protein or said operative parts thereof in monitoring
or controlling PCR

FIELD OF INVENTION

The present invention relates to a novel enzyme present in
cod liver, a DNA sequence encoding the enzyme or operative
parts thereof, a novel recombinant DNA comprising the gene
or the operative parts thereof, a method of preparing the
enzyme from cod liver and from bacteria carrying the gene,
the bacteria carrying the gene per se, and the use of the
protein in monitoring and/or controlling PCR or related
reaction systems.

Description Of Prior Art

Uracil-DNA glycosylase (UNG or UDG) catalyses the
hydrolysis of the N-glycosylic bond between the deoxyribose
sugar and the base in uracil containing DNA, and was first
isolated and characterized from *Escherichia coli* (1). This
is the first step in the base excision repair (BER) pathway
of removing uracil from DNA (2), and the apyrimidinic site
generated is thereafter repaired by an AP endonuclease,
phosphodiesterase, DNA polymerase and DNA ligase (other
enzymes) in the BER-pathway (3-5).

Several classes of uracil-DNA glycosylases (UNG) have been
described. The major cellular form of UNG is UNG encoded by
the UNG-gene (6). Other classes consist of cyclin like
human UDG2 (7,8), single strand selective monofunctional
UNG SMUG1 from human and *Xenopus* (9), G/T:U specific
mismatch DNA glycosylase (MUG) isolated from *E. coli*
(10,11), and *Thermotoga maritima* UDG (TMUDG) (12).

UNG is a monomeric protein, about 25-35 kD in size. It is not dependent on any cofactors and is highly conserved among different species (13). UNG is however affected by ionic strength. The UNG enzyme has both been shown to act in a processive "sliding mechanism", where it locates sequential uracil-residues prior to dissociation from the DNA (14) (15), and a distributive "random hit" mechanism (16). UNG has previously been isolated and characterized from rat liver (17-19), human cells and tissues (20-28), calf thymus (29,30), slime mold, (31), yeast (32), plants (33,34), brine shrimp (35), procaryotes (1,36-45) and viruses (46,47).

In human and rat, both a mitochondrial and a nuclear UNG have been isolated (18,25). In human (and mouse) cells these two are encoded by the same gene (UNG) (48) (49). By using two different transcription start sites and alternative splicing, two forms are generated which differ only in the N-terminal signal sequence, which targets the enzyme to the nucleus (UNG2) and mitochondria (UNG1), respectively (49). Recently, several studies have been done to further study the N-terminal signal sequences and the targeting of UNG to the nucleus and mitochondria (50-52), revealing the nuclear UNG2 to be phosphorylated (26). The crystal structures of UNG from human, herpes simplex virus and *E. coli* have been solved (53-55). The active site residues are conserved and the mode of action in these enzymes seems to be the same with a nucleotide flipping mechanism to remove uracil from DNA (56) (57).

Enzymes from cold adapted organisms, such as the Atlantic cod (*Gadus morhua*), have to compensate for the reduction of chemical reaction rates at low temperatures in order to maintain sufficient metabolic activities. This can be achieved by a higher transcription/translational levels, or improved catalytic efficiency (k_{cat}/K_M). Higher catalytic efficiencies can be reached by a more flexible structure, compared to their mesophile counterparts, which provides

enhanced ability to undergo conformational changes during catalysis. The reduced stability to pH, temperature and denaturing agents is regarded as a consequence of a higher conformational flexibility (58).

5 The present invention concerns the purification and characterization of a heat-labile uracil-DNA glycosylase from a cold-adapted organism, and which has utility as an enzyme efficient in carry-over prevention in DNA-copying reactions (PCR, LCR etc.). The enzyme isolated according
10 to the present invention has similar characteristics as previously described UNGs with respect to molecular weight, isoelectric point, pH and NaCl-optimum. However, the enzyme according to the present invention has been shown to be more pH-labile and heat-labile and has a higher relative
15 activity at low temperatures, compared to a recombinant mesophilic human UNG, making it a better candidate in carry-over prevention tests as indicated supra.

UNG from *Escherichia coli* has been commercially available for use in carry-over prevention when amplifying DNA
20 material.

Various techniques may be employed to amplify specific DNA sequences on basis of a DNA template. Common techniques are the polymerase chain reaction (PCR) system (US patent Nos. 4.683.195; 4.683.202; and 4.965.188), the ligase
25 amplification system (PCT patent publication No. 89/09835), the self-sustained sequence replication system (EP No. 329.822 and PCT patent publication No. 90/06995), the transcription-based amplification system (PCT patent publication No. 89/01050 and EP No. 310.229) and the Q β RNA
30 replicase system (US patent No. 4.957.858). These techniques are very sensitive in that they may produce detectable DNA amounts from very few copies of a target DNA sequence. Accordingly the techniques are very sensitive to contamination by DNA from the environment. The major

source of contamination is products from previously performed up-scaling reactions, e.g. PCR reactions (59).

To overcome this problem a method to discriminate between target DNA and contaminating DNA from prior reactions, e.g. PCR product DNA, has been developed (60). In essence, all amplification reactions are carried out using dUTP to replace dTTP thus incorporating uracil into DNA in place of thymidine. All subsequent reaction mixtures are then treated with UNG. A following heat treatment degrades the contaminating DNA by hydrolysis of the phosphodiester bond at abasic sites. Also, the heat treatment is supposed to inactivate the UNG enzyme.

However, the UNG enzyme from *E. coli* is not completely inactivated by heat treatment, and the inactivation is not completely irreversible ((60), US patent No. 5,035,996). This affects the upscaling reaction, e.g. PCR reaction, product integrity, since the products are degraded by residual UNG enzyme activity. In order to avoid this, the subsequent addition of enzyme inhibitor to UNG has been used (US patent No. 5,536,649).

However, it would be preferable to avoid using the subsequent inhibitor because this represents an extra step in the reaction procedure, residual contamination by the inhibitor may be present in subsequent reactions, and the purchase of inhibitor represents an extra cost when performing a PCR reaction as disclosed supra.

Thus it would be preferable to use an UNG enzyme which is certain to be destroyed/inactivated by the heat treatment following the PCR reaction, thus avoiding the addition of specific chemical inhibitors for the UNG enzyme.

OBJECTS OF THE INVENTION

It is an object of the present invention to provide a novel UNG enzyme which is functional in carry-over prevention techniques for DNA amplification reactions, e.g. PCR, indicated supra, and which is completely and irreversibly inactivated by the heat treatment normally performed in PCR reaction cycles.

Furthermore it is an object of the present invention to provide a DNA sequence coding for such an enzyme or an active part thereof, a vector or vector system (e.g. a virus, a plasmid, a cosmid, etc.) carrying such a DNA sequence and a microorganism including such a vector.

It is also an object of the present invention to provide a method for efficient production of the enzyme or an active part thereof by using genetic engineering techniques.

DETAILED DESCRIPTION OF THE INVENTION

Enzymes from cold adapted organisms living in cold habitats, such as the Atlantic cod (*Gadus morhua*), have to compensate the reduction of chemical reaction rates at low temperatures to maintain sufficient metabolic activities. This can be done by a higher transcription/translational level, or improved catalytic efficiency (k_{cat}/K_M). This higher efficiency is reached with a more flexible structure, compared to their mesophile counterparts, which provides enhanced ability to undergo conformational changes during catalysis. The reduced stability to pH, temperature and denaturing agents is regarded as a consequence of the conformational flexibility (58).

In view of the disadvantages with contaminations of UNG according to prior art in carry-over prevention procedures when amplifying DNA sequences (PCR, LCR) it would be very convenient to provide a UNG enzyme which was 100% degraded

by simple heat treatment. It has now been found that an UNG enzyme isolated from cod has this valuable property. The cod-UNG enzyme isolated according to the present invention has a similar molecular weight, isoelectric point, pH- and NaCl-optimum as previously described UNGs, but the present cod-UNG is more pH- and heat-labile and has a higher relative activity at low temperatures as compared to a recombinant mesophilic human UNG. The heat lability of the present enzyme may be further tested in a functional assay using the procedure of Sobek et al. (45).

Infra is disclosed an isolation procedure for the relevant cod UNG protein according to the invention as well as isolation of DNA coding for this protein and its use in microorganisms for producing recombinantly the relevant UNG enzyme according to the invention is disclosed.

Material And Methods

Q-Sepharose FF, S-Sepharose FF, Heparin Sepharose HP (Hi-trap 5 ml), Poly-U-Sepharose 4B, Superdex 75 HR10/30, Phast system and Phast IEF gels (3-9) and LMW gel filtration calibration kit were obtained from Amersham Pharmacia Biotech (Uppsala, Sweden). Deoxy[5-³H]uridine 5'-triphosphate (19.3 Ci/mmol) was purchased from Amersham (U.K). Uracil-DNA glycosylase inhibitor (Ugi) was obtained from New England Biolabs (Beverly, MA), enzymes were purchased from Promega (Madison, WI). Protease inhibitors, calf-thymus DNA (D-1501), uracil, deoxyuridine and deoxyuridine-monophosphate were purchased from Sigma (St. Louis, MO). All other reagents and buffers were purchased from Sigma and Merck (Darmstadt, Germany).

Purification Of cUNG

Preparation of crude extract and all purification steps were performed at 4 °C.

Preparation Of Crude Extract

To 600 ml extract buffer (25 mM Tris/HCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol, pH 8.0) 200 g of fresh cod liver was added and homogenized in an Atomix
5 homogenizer (MSE, England). Before homogenization, the following protease inhibitor mix was added to the extract buffer: 1 mM PMSF, 1 μ M pepstatine, 1 μ M leupeptine, 10 μ M TPCK and 10 μ M TLCK (final concentrations). The homogenate was centrifuged at 28,000 g for 15 min and the supernatant
10 was filtered through glasswool. Finally glycerol was added to 30% (v/v), and the cod liver crude extract was frozen at -70 °C.

Q-Sepharose Fast Flow

One liter crude extract was diluted with 1 liter buffer A
15 (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1% (v/v) glycerol, pH 8.0 (Fraction 1). The sample was applied in two portions (1 liter each) on a Q-Sepharose FF column (5.0/15), equilibrated with buffer A, and then washed with 250 ml buffer A, using a flow-rate of 10 ml/min. Proteins bound to
20 the column were eluted with 200 ml buffer A + 1.0 M NaCl, and the column was re-equilibrated with buffer A before the next part of the sample was applied, as mentioned above. The UNG-containing flowthrough and wash fractions from both
two runs were pooled (Fraction 2, 2340 ml).

25 S-Sepharose Fast Flow

Fraction 2 was applied to a S-Sepharose FF column (1.6/10) equilibrated in buffer A, flow rate 10 ml/min. The column was washed with 300 ml buffer A + 60 mM NaCl, and eluted using a 200 ml linear gradient of 0.06-0.4 M NaCl in buffer
30 A, flow-rate 5 ml/min. UNG-containing fractions were pooled (55 ml) and dialyzed overnight in buffer A (Fraction 3).

Heparine Sepharose HP

Fraction 3 was applied to a Heparine Sepharose HP Hi-Trap column (1.6/2.5) equilibrated in buffer A. The column was washed with 50 ml buffer A + 60 mM NaCl and was eluted in a
 5 50 ml linear gradient of 0.06-0.4 M NaCl in buffer A, flow-rate 1 ml/min. UNG-containing fractions were pooled (Fraction 4, 20 ml).

Poly-U Sepharose (4B)

Fraction 4 was then diluted 5 times in buffer A, and
 10 applied to a Poly-U Sepharose column (1.6/10) equilibrated in buffer A. The column was washed with 60 ml buffer A + 60 mM NaCl and was eluted in a 200 ml linear gradient of 0.06-0.4 M NaCl in buffer A, flow-rate 1 ml/min. UNG- containing fractions were pooled (Fraction 5, 70 ml).

Superdex 75

Fraction 5 was concentrated to 200 μ l using Ultrafree15 and Ultrafree-MC ultracentrifugation filters (Millipore), cutoff 5K, and applied on the gel filtration column (HR 1.0/30) equilibrated in buffer A, with a flow-rate of 0.5
 20 ml/min. Fractions (350 μ l) were collected, and those containing UNG-activity were pooled (Fraction 6, 3 ml).

Preparation Of Substrate By Nick-Translation

³H-dUMP DNA was prepared by nick-translation and polymerase chain reaction (PCR). The nick translated substrate was
 25 made in a total volume of 1 ml and contained 50 mM Tris/HCl, pH 7.2, 10 mM MgSO₄, 1 mM DTT, 250 μ g calf thymus DNA (purified by phenol/chloroform extraction and ethanol precipitated prior to use), 0.1 mM dATP, dCTP, dGTP and dUTP, where 3 μ M of the dUTP was [³H]-dUTP (19.3
 30 Ci/mmol). The reaction was initiated by adding 0.1ng (5.35x10⁻⁴ U) DNase I (bovine pancreas, Promega), and 30

seconds later 25 U of E. coli DNA polymerase. The nick-translation mix was incubated at 21 °C for 24 hours. The nick-translated DNA was purified by phenol/chloroform extraction, and ethanol precipitation. DNA was resuspended
5 in 50 µl TE-buffer and purified using a NAP-5 column (AP Biotech) equilibrated in TE-buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0) to remove unincorporated nucleotides. Specific activity of the Nick-substrate was 1.8×10^5 dpm/µg (425 cpm/pmol).

10 Preparation Of Substrate By PCR

The PCR-produced substrate was used for all characterization experiments and consisted of a 761 bp fragment generated from cationic trypsinogen (sstrpIV) from Atlantic salmon (Salmo salar) (61). The PCR was carried out
15 in a volume of 50 µl in a Perkin Elmer Cetus thermocycler. The PCR-mix contained 10 mM Tris/HCl, pH 8.3, 50 mM KCl, 6 mM MgCl₂, 0.37 mM dATP, dCTP, dGTP and dUTP, where 10.4 µM of dUTP was [³H]-dUTP (17.0 Ci/mmol, Amersham), 700 pg template DNA (sstrpIV in a pgem7zt-vector), 2.5 µM of
20 upstream and downstream primers and 2 U Taq-polymerase (Roche, Switzerland). The PCR-reaction was done by 30 cycles of 94 °C for 1 min, 45 °C for 1 min and 72 °C for 1 min. Then an additional 2 U of Taq-polymerase was added and the PCR-reaction continued with 30 new cycles as described
25 above. The PCR-substrate was purified with QIAquick PCR-purification kit (Qiagen) as described by manufacturer, and eluted in 50X diluted TE-buffer, pH 8.0. Specific activity of the PCR-substrate was 5.9×10^5 dpm/µg (451 cpm/pmol). All characterization experiments were done using the PCR-
30 substrate.

Detection Of Uracil-DNA Glycosylase Activity (Standard Assay)

Uracil-DNA glycosylase activity was measured in a final volume of 20 µl, containing 70 mM Tris/HCl, 10 mM NaCl, 1

mM EDTA, 100 µg/ml BSA and 230 ng nick-substrate or 71 ng PCR-substrate. The reaction mixture was incubated 10 min at 37 °C, and terminated with the addition of 20 µl of ice cold single stranded calf thymus DNA (1 mg/ml) and 500 µl 10% (w/v) TCA. Samples were incubated on ice for 15 min, and centrifuged at 16,000 g for 10 min. Supernatants with acid soluble ³H-uracil were analyzed using a liquid scintillation counter.

One unit of activity is defined as the amount of enzyme required to release 1 nmol of acid soluble uracil per minute at 37 °C.

Analysis Of Assay Products With Thin Layer Chromatography

Reaction products after assays were mixed with 20 nmol uracil, deoxyuridine and deoxyuridine- monophosphate. Thin layer chromatography was performed according to the method by Wang and Wang, using polyamide layer plates (BDH), and tetrachloromethane, acetic acid and acetone (4:1:4, by volume) as solvent (62). Spots detected under UV-light were cut out of the plate and radioactivity measured in a liquid scintillation counter.

Molecular-Weight Determination

The molecular weight was determined by gel-filtration, and was performed with a Superdex 75 column (1.0/30) equilibrated in a buffer containing 25 mM Tris/HCl, 1.0 M NaCl, 1 mM EDTA, 1% (v/v) glycerol, pH 8.0. The flow-rate was 0.5 ml/min, and activity was measured in the fractions collected (250 µl). Bovine serum albumin (BSA, 67 kD), ovalbumin (43 kD), chymotrypsinogenA (25 kD) and ribonucleaseA (13.7 kD) were used as standards. Blue dextran and sodium chloride were used to determine void- (V_0) and intrinsic volume (V_i), respectively.

Protein Determination

Protein concentrations were determined with Coomassie® Protein Assay Reagent G-250 (Pierce, New York, NY) by the method of Bradford (63), with the microtiter plate protocol as described by manufacturer, using bovine serum albumin (BSA) as a standard.

Isoelectric Point Determination

Isoelectric point determination was done with the Phast-system, isoelectric focusing gel 3-9 and silver stained according to methods described by manufacturer. Standards used were phycocyanin (4.45, 4.65, 4.75), β -lactoglobulin B (5.10), bovine carbonic anhydrase (6.00), human carbonic anhydrase (6.50), equine myoglobin (7.00), human hemoglobin A (7.10), human hemoglobin C (7.50), lentil lectin (7.8, 8.0, 8.2), cytochrome c (9.6), (IEF Standards pI range 4.45-9.6, BIO-RAD). After focusing, the gel was cut into 2 mm pieces and each incubated in 250 μ l extraction buffer (50 mM Tris/HCl, 0.2 M NaCl, 1 mM DTT, 1 mM EDTA, 1% (v/v) glycerol, pH 8.0 overnight. Aliquotes of 5 μ l were transferred to the assay mixtures, and activity measured using standard assay conditions.

Determination Of pH/NaCl-Optimum

Assays were done in a volume of 20 μ l as described in standard assay using the PCR generated substrate and NaCl concentration from 0-200 mM with 25 mM intervals, and pH ranging from 9.5-6.5 with 0.5 pH unit intervals. All buffers were supplemented with 100 μ g/ml BSA and 1 mM EDTA. The buffers used were diethanolamine/HCl (9.5-8.5), Tris/HCl (8.5-7.5) and MOPS/NaOH (7.5-6.5). All buffers were pH adjusted at 37 °C and used in 25mM concentration in the assay.

Determination Of Temperature Optimum

Assays were done in a volume of 20 μ l as described in standard assay using the PCR generated substrate. The assay mixtures were as described in standard assay conditions and
 5 were adjusted to pH 8.0 for all temperatures. The temperature range used was 5 °C to 60 °C. The activity was measured in a sequential manner with 15 min intervals between each temperature. The enzymes used were diluted in standard dilution buffer (5 mM Tris/HCl, 10 mM NaCl, 1%
 10 (v/v) glycerol, pH 8.0) and placed on ice. Due to the instability of the enzyme sample on ice over a prolonged period, results were corrected with respect to the stability of the enzymes incubated in dilution buffer on ice, with the formula $N_{(t)} = \text{cpm} / e^{-0.693(t/\lambda)}$, where half-life
 15 (λ) of cUNG and rhUNG are 2.0 hours and 2.6 hours respectively.

Effect Of pH And Temperature On Stability

pH: UNG (0.01 U) was preincubated (in a total volume of 75 μ l) for 10 min at 37° in buffers containing 10 mM buffer,
 20 10 mM NaCl, 1 mM EDTA, 1% (v/v) glycerol, with pH ranging from 9.5-6.5 with 0.5 pH unit intervals using diethanolamine/HCl (9.5-8.5), Tris/HCl (8.5-7.5), MOPS/NaOH (7.5-6.5) and MES/NaOH (6.5-5.5) as buffer components.
~~Aliquots of 5 μ l were transferred to the assay mixtures and~~
 25 residual activity was measured using standard assay conditions.

Temperature: UNG (0.01 U) was preincubated (in a total volume of 75 μ l) in 10 mM Tris/HCl, 50 mM NaCl, 1mM EDTA, 1% (v/v) glycerol, pH 8.0 (adjusted at each temperature).
 30 After different time intervals, as indicated in figure legends, 5 μ l aliquots were transferred to the assay mixtures and residual activity was measured using standard assay conditions.

Substrate Specificity Against ss/ds DNA

PCR and Nick-translated substrate was incubated 3 min at 100 °C and thereafter rapidly cooled on ice to generate ssDNA. Following denaturation, the ssDNA-substrates were
5 used in standard assay condition with 6.65×10^{-4} U purified cUNG. Enzyme activity was also measured using dsDNA-substrates for both Nick- and PCR-substrate, and used as references.

Ugi Inhibitor- And Uracil Product Inhibition

10 Activity measurements using PCR-substrate were performed with 6.65×10^{-4} U of purified cUNG. Various concentrations of uracil (0, 1, 2 and 5 mM) or Ugi-inhibitor (1.25×10^3 U to 2.00×10^2 U) were added to the assay mixtures (on ice). Activity was then measured as described under standard
15 assay conditions.

RESULTS

Purification Of cUNG

Atlantic cod UNG was purified 17,000 fold with a recovery of 2%, as shown in Table 1. Despite the high purification
20 factor, the enzyme was only partly purified as determined by SDS-PAGE. The yield was low, due to the many purification steps, and the concentration of the dilute protein sample prior to the gel-filtration step.

Molecular Weight And pI-Determination

25 The molecular weight was determined by gel filtration to be $25 \text{ kD} \pm 2$, from three separate experiments. The isoelectric point determination was done with an IEF Phast Gel with IEF standards ranging from 4.42 - 9.6. Following IEF, cUNG activity was eluted from the gel fragments and activity
30 measured as described in material and methods. cUNG

activity co-eluted with the cytochrome c, standard with an isoelectric point of 9.6, as shown in Fig. 1. The cytochrome c and cUNG activity were found where the electrode contacted the gel, therefore we can only conclude that the pI is larger than 9.0, which is the highest measurable value using this system.

Substrate Specificity

cUNG activity was measured using both ssDNA and dsDNA. A 1.8 and 1.9 fold higher activity for ssDNA than dsDNA was found using Nick- and PCR- substrates, respectively, as shown in Table 2. Assay products were analyzed by thin layer chromatography, and the major part of the radioactivity was identified as uracil. However, some radioactivity was also co-localized with the deoxyuridine marker, but this could be due to the partial overlap of the two markers. In addition the purified cUNG did not exhibit any significant hydrolysis of ³H-adenine-labelled DNA, therefore excluding nucleases as responsible for hydrolyzing the DNA.

Inhibition Studies

Product inhibition by free uracil was examined, and gave more than 50% inhibition with 1 mM uracil in the assay mixture, as shown in Fig. 2. Adding 5 mM free uracil to the assay mixture, a 78% inhibition of the activity was observed. The effect of Ugi on cUNG was measured by adding Ugi to the assay mixture. cUNG was clearly inhibited by Ugi, as shown in Fig. 3.

pH And NaCl Optimum

The pH and sodium chloride optimum was examined by measuring the enzyme activity at different pHs using NaCl-concentration from 0-200 mM, as shown in Fig. 4. The enzyme exhibited a broad pH-optimum, with maximal activity between

pH 7.0-9.0, and 25-50 mM NaCl. A shift in NaCl optimum was observed, where the optimum NaCl concentration changed from low concentrations at high pH to higher concentrations at low pH. At pH 9.5 cUNG was inhibited by NaCl.

5 Temperature Optimum

The temperature optimum of cUNG was determined to 41 °C (Fig. 5). To compare the activity of cUNG with the mesophilic rhUNG at low temperatures, enzyme activity was measured from 5-60 °C, and the activity at low temperatures compared to their respective optimum temperature (Fig. 6). The activity profile of these two enzymes showed little difference at 5-15 °C. However at temperatures from 20-40 °C, a higher relative activity was observed with cUNG than rhUNG, whereas at high temperatures (50-60 °C) the opposite was observed.

Stability

The stability of the two UNG enzymes were compared by preincubating the enzymes at different pHs. Atlantic cod UNG was shown to be most stable between pH 7.0-8.5. At pH 5.5 and pH 10.0 it had less than 1% residual activity. rhUNG was most stable between pH 7.0-9.5. At pH 5.5 only 3% residual activity remained, but at pH 10.0, as much as 66% of the activity remained, as shown in Fig. 7. The temperature stability of the two UNG-enzymes was compared at 4 °C, 25 °C, 37 °C and 50 °C. At 50 °C, the half-life was determined to be 0.5 min and 8 min for cUNG and rhUNG respectively. At all temperatures examined, rhUNG was more stable than cUNG. Half-lives determined were 20 min (37 °C), 60 min (25 °C) and 2 h (4 °C) for cUNG and 30 min (37 °C), 150 min (25 °C) and 2.6 h (4 °C) for rhUNG. The largest difference in half-life was found at the highest temperature, as shown in Fig. 8.

DISCUSSION

Purification And Molecular Weight

The uracil-DNA glycosylase from Atlantic cod liver (*Gadus morhua*) was purified 17,679 fold using several chromatographic techniques. Still the enzyme was only partly purified, as several other bands were seen on a SDS-PAGE gel. Human nuclear and mitochondrial uracil-DNA glycosylases are shown to be generated by alternate splicing, and have a ORF of 313 and 304 amino acids respectively (49). The molecular weight of cUNG was determined to 25 kD. This is approximately the same molecular weight as determined for the UNG from human placenta (29kD) and the rhUNG (UNGΔ84) (27kD), which lacked 77 and 84 of the first N-terminal amino acids respectively, as predicted from the mitochondrial ORF (21,64). This suggest that the N-terminal signal sequence in the purified cUNG is processed or artificially cleaved during purification or that Atlantic cod UNG does not have a N-terminal signal sequence. During purification we did not see any sign of two different UNGs as previously described during purification of UNG from rat or human sources (18,23). But as a vertebrate, one should expect that Atlantic cod possesses both a nuclear and a mitochondrial form of UNG, but so far no effort has been given to reconcile this matter.

The uracil-DNA glycosylase from Atlantic cod was similar to other uracil-DNA glycosylases previously purified and characterized with respect to the high pI (19) and the two-fold preference to ssDNA than dsDNA (19).

Inhibition By Ugi And Uracil

The *Bacillus subtilis* bacteriophage PBS2 UNG-inhibitor (Ugi) inhibits UNG by forming a stable complex with UNG at physiological conditions (65,66). Ugi binds to human UNG by

inserting a beta-strand into the conserved DNA binding groove (67), and act by mimicking DNA (68). This indicates that the structure of the substrate binding site of cUNG is similar to other UNGs inhibited by the Ugi-inhibitor.

- 5 Inhibition with free uracil was in agreement with values previously reported (19).

Optimum Conditions

cUNG was shown to have a broad pH optimum from 7.0-9.0, and the activity was strongly affected by NaCl-concentration. A
 10 broad pH-optimum has previously been reported for several other UNGs characterized (23,31,40,47). Interestingly the NaCl-optimum for cUNG increases as pH decreases. It has previously been demonstrated that UNG functions in a processive manner at low ionic strength, which as NaCl-
 15 concentration increases the enzyme switches to a distributive mechanism (14) (15). However Purmal et al reported the opposite, that UNG acted in a distributive mechanism at low ionic strength. The processive mechanism is a common feature among several DNA interactive proteins
 20 (polymerases, repressors, restriction/ modification enzymes, DNA repair enzymes), and the interactions are generally electrostatic in nature (69-71). In a UV-endonuclease from *Micrococcus luteus* the processive mechanism has also been shown to be pH-dependent (72).

25 Therefore we suggest that the shift in NaCl-optimum with increasing pH reflects the processive/distributive nature of cUNG. And it could be that the controversy in the previous reports are also due to different buffer components and pH, in addition to the differences already
 30 discussed.

The temperature optimum (41 °C) was found to be slightly lower than the mesophilic rhUNG (45 °C) (64). The relative activity at temperature from 5-45 °C was higher for cUNG than rhUNG. At temperatures higher than 45 °C, rhUNG shows

a higher relative activity than cUNG, presumably as a consequence of the low temperature stability of cUNG.

Temperature And pH Stability

Enzymes characterized from cold-adapted species have been
5 found to be more temperature and pH-labile, proposed due to
their flexible structure in order to maintain enzymatic
activity at low temperatures (73). cUNG was found to be
both more pH- and temperature labile than the rhUNG, which
are known features for other cold-adapted enzymes (73,74).
10 A psychrophilic UNG from a marine bacterium has previously
been isolated, and was compared to *E.coli* UNG with respect
to temperature stability (45). This procaryotic UNG had a
half-life of 2 min at 40 °C and 0.5 min at 45 °C, compared
to 27 and 8 min for the *E.coli* UNG. cUNG was compared to
15 the rhUNG with respect to both temperature and pH
stability. At 50 °C rhUNG had a half-life of 8 min,
compared to 0.5 min for cUNG. At lower temperature the
difference in half-life was less, although rhUNG was more
stable than cUNG at all temperatures examined. Both enzymes
20 were shown to be labile at low pH, whereas at high pH rhUNG
was more stable than cUNG.

In conclusion, the uracil-DNA glycosylase from Atlantic cod
~~was shown to be similar to other uracil-DNA glycosylases~~
previously purified and characterized with respect to
25 molecular weight, high pI, a broad pH-optimum and a two-
fold preference to ssDNA than dsDNA. However the cUNG was
shown to be more temperature and pH-labile and has a higher
relative activity at low temperatures than the mesophilic
rhUNG. Take into consideration that UNG is a conserved
30 enzyme among different species, cUNG could be a suitable
enzyme for further studies of cold-adaption at the
molecular level.

Isolation Of The Uracil-DNA Glycosylase Gene From Gadus Morhua

MATERIALS

SuperScript™ II RNase H⁻ Reverse Transcriptase (Gibco
5 BRL), Packagene® Lambda DNA packaging system was purchased
from Promega (Madison, WI), Deoxy[5-³H]uridine 5'-
triphosphate (17.0 Ci/mmol) was purchased from Amersham
(England), expression vector pTrc99A and FPLC system and
10 columns were purchased from Amersham Pharmacia Biotech
(Uppsala, Sweden), restriction enzymes were purchased from
New England Biolabs (Beverly, MA), SMART™ PCR cDNA Library
Construction kit and Marathon™ cDNA Amplification Kit were
purchased from Clontech (Palo Alto, CA). *Escherichia coli*
NR8052 [Δ (*pro-lac*), *thi*-, *ara*, *trpE9777*, *ung1*] (75,76) and
15 purified recombinant human UNG (UNG Δ 84) (64) was kindly
provided by Dr. Hans E. Krokan, Institute for cancer
research and Molecular Biology, Norwegian University of
Science and Technology.

METHODS

20 Isolation Of mRNA

mRNA was isolated from 250 mg cod liver using Oligotex
direct-mRNA-Midi kit (Qiagen), following the instructions
in manufacturers protocol.

Preparation Of cDNA

25 cDNA was made from 250 ng of the isolated poly A⁺ RNA using
SMART™ PCR cDNA Library Construction kit (Clontech)
according to the protocol recommended by the manufacturer.
In brief, 1st strand cDNA was made by combining 250 ng poly
A⁺ RNA with 10 pmol SMART oligonucleotide (5'-
30 TACGGCTGCGAGAAGACGACAGAAGGG-3') and 10 pmol CDS/3' PCR
primer (Oligo(dT)30 N -1 N (N = A, G, C, or T; N -1 = A, G,

or C)) in a final volume of 5 μ l, and incubated at 72°C for 2 min and then placed directly on ice for 2 min to denature the RNA. Then enzyme and buffer were added to the reaction mixture to a final volume of 10 μ l, consisting of 50 mM Tris/HCl, pH 8.3, 6 mM MgCl₂, 75 mM KCl, 2 mM DTT, 1 mM dATP, dCTP, dGTP and dTTP respectively and 200 U SuperScript™ II reverse transcriptase (Gibco BRL), and then incubated at 42°C for 1 h. Synthesis of 2nd strand was done by PCR in a final volume of 100 μ l, containing 2 μ l of the 1st strand reaction as template, 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 μ g/ml BSA, 0.2 mM of dATP, dCTP, dGTP and dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 0.2 μ M 5'-PCR primer (5'-TACGGCTGCGAGAAGACGACAGAA-3') and CDS/3'-PCR primer respectively.

PCR amplification was done in a GeneAmp 9700 thermocycler (Perkin Elmer), by 95°C for 1 min followed by 16 cycles of 95°C for 15 sec and 68°C for 5 min.

ds cDNA polishing To 50 μ l of the amplified ds cDNA, 40 μ g proteinase K was added and incubated at 45°C for 1 h. Proteinase K was inactivated by incubating the mixture at 90°C for 8 min. To blunt end the ds cDNA, 15 U of T4 DNA polymerase was added and incubated at 16°C for 30 min and 72°C for 10 min. Finally the ds cDNA was ethanol precipitated and resuspended in 10 μ l H₂O. All tubes were kept on ice if not otherwise stated.

Generation Of A 300 bp Fragment Of The cUNG-Gene

Degenerated oligonucleotide primers were designed from two conserved regions (GQDPYH and VFLLWG) from known UNG- amino acid sequences. Codon usage for Atlantic cod were also considered when designing the primers. The UNG fragment was generated by PCR with cod liver cDNA as template in a final volume of 50 μ l, containing 10 mM Tris/HCl pH 9.0 (25°C), 50 mM KCl, 0.1% Triton X-100, 10 ng cDNA, 0.2 mM dATP,

dCTP, dGTP and dTTP respectively, 2.0 μ M upstream primer (5'-GGH-CAR-GAY-CCC-TAY-CA-3') and downstream primer (5'-DCC-CCA-SAG-SAG-RAA-VAC-3') respectively and 2.5 U Taq-polymerase (Promega). PCR was carried out by 94°C for 4 min, 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final extension step of 72°C for 5 min.

DNA Sequencing

DNA sequencing was done with the Amersham Pharmacia Biotech Thermo Sequenace Cy5 Dye Terminator Kit, ALFexpress™ DNA sequencer and ALFwin Sequence Analyzer version 2.10. Gels were made with ReproGel™ Long Read and Reproset UV-polymerizer. All items were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).

RACE Procedure

Ligation of adapters to cDNA was done as described in the protocol from the manufacturer. In brief, RACE-adaptors were ligated to cDNA in a total volume of 10 μ l containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 0.75 μ g cDNA, 2 μ M Marathon cDNA adapter (Clontech), 400 U T4 DNA ligase. The reaction was incubated at 16°C for 16 h, and 5 min at 70°C to inactivate the ligase. Before RACE, the adapter ligated cDNA was diluted 50 times in TE-buffer and denatured at 100°C for 2 min and placed directly on ice.

The sequence deduced from the 300 bp fragment of the UNG-gene was used to design two primers for both 3'- and 5'-rapid amplification of cDNA ends (RACE), with a small overlap region between the two fragments generated. Both 3'- and 5'-RACE reactions were done in a volume of 50 μ l with 1 μ l of diluted cDNA with RACE-adapters as template, 0.2 μ M internal 3'- (5'-TGTACCGACATTGATGGCTTCAAGCAT-3') or 5' (5'-CCCATCCGCTTAGATCTCCATGTCCAG-3') RACE primers, respectively, 0.2 μ M AP1-primer (supplied by

manufacturer) (5'-CCATCCTAATACGACTCACTATAGGGC-3'), 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of each dATP, dCTP, dGTP and dTTP and 1U Advantage cDNA Polymerase Mix (Clontech).

5 Amplification was done in a GeneAmp 9700 thermocycler (Perkin Elmer), 94°C for 30 sec followed by 5 cycles of 94°C for 5 sec and 72°C for 3 min, 5 cycles of 94°C for 5 sec and 70°C for 3 min, and 20 cycles of 94°C for 5 sec and 68°C for 3 min.

10 (Individual bands were purified from an agarose gel, and used as template in a new PCR-reaction with the same conditions as above to generate more DNA.)

Isolation Of Two Different UNG Genes

Both RACE-fragments generated were sequenced using their
 15 respective internal RACE-primers. Examining the sequence of the 5'-RACE-fragment indicated a double sequence, difficult to read, near the 5'-end of the fragment. However at the end of the fragment only one sequence appeared, due to a long UTR in one of the UNG-sequences but not the other. A
 20 new primer complementary to this 5'-end was designed (5'-ATGGAATTCGATTGAGATTGGCGCCTTTGG -3') and a new PCR-reaction was carried out with this, and the 5'-RACE internal primer, with the 5'-RACE fragment as template. The PCR was carried
 out in a final volume of 50 µl with 40 mM Tricine/KOH pH
 25 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of dATP, dCTP, dGTP and dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 10 ng cDNA as template and 0.2 µM upstream and downstream primers respectively. Amplification was done in a GeneAmp 9700
 30 thermocycler (Perkin Elmer), 94°C for 1 min. followed by 30 cycles of 94°C for 30 sec, 60°C for 1 min and 72°C for 1 min.

The fragment was sequenced using the internal RACE-primer, and the sequence was subtracted from the double sequence

region described above. A primer complementary to the 5p-end of the underlying sequence was designed (consisting of both nucleotides from the SMART-sequence and the remaining UNG-sequence), and a PCR-reaction with this and the
5 internal 5'-RACE-primer was carried out. The new fragment was sequenced as described above. From the two different UNG-sequences in the 5'-RACE-fragment, two final primers (UNG1 and UNG2) were made to isolate the full length UNG1 and UNG2, respectively, using cDNA as template and the same
10 PCR-conditions as described above.

Construction Of Expression Vectors

The catalytic domain of the UNG-gene was cloned in the expression vector pTrc99A, containing a strong trc promoter upstream of a multiple cloning site (77). Several different
15 constructs were made by PCR-amplifying the gene using cDNA as template with upstream and downstream primers containing EcoRI and SalI restriction sites respectively. DNA-fragments were purified, digested with EcoRI and SalI and ligated into the pTrc99A expression vector. In brief, PCR-
20 fragments with restriction sites were generated in a PCR-reaction (50 µl) containing 40 mM Tricine/KOH pH 9.2 (25°C), 15 mM KOAc, 3.5 mM Mg(OAc)₂, 3.75 µg/ml BSA, 0.2 mM of dATP, dCTP, dGTP and dTTP respectively, 1U Advantage cDNA Polymerase Mix (Clontech), 10 ng cDNA as template and
25 0.2 µM upstream and downstream primers respectively. Amplification was done in a GeneAmp 9700 thermocycler (Perkin Elmer), 94°C for 1 min followed by 30 cycles of 94°C for 30 sec, 60°C for 1 min and 72°C for 2 min, and a final extension step of 72°C for 5 min. Individual bands
30 were purified from agarose gel, and used as template in a new PCR-reaction, with the same conditions as described above, to generate more DNA. DNA was purified using Quiaquick PCR purification kit (Millipore) as described by manufacturer, and eluted in TE-buffer, pH 8.0. Restriction
35 enzyme digestion was done in a final volume of 30 µl containing 1 µg insert DNA or 0.25 µg pTrc99A vector, 6 mM

- Tris/HCl, pH 7.9, 6 mM MgCl₂, 150 mM NaCl, 1 mM DTT (BufferD, Promega) and 3U of EcoRI and SalI. The mixtures were incubated at 37°C for 3 h, followed by two times phenol/chloroform extraction, ethanol precipitation and resuspended in 5 µl H₂O. Ligations were performed in a total volume of 10 µl containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 100 U T4 DNA ligase, 250 ng vector DNA and 1 µg insert DNA, and incubated at 16°C for 16 h.
- Competent *E. coli* JM105 (200 µl) was transformed with ligation mixes and grown on LB+ plates containing 100 µg/ml ampicillin at 37°C. Plasmid DNA was reisolated from positive clones and transformed in *E. coli* NR8052 used for expression of recombinant UNG.
- Four different constructs were made rcUNGA74 and rcUNGA74o and rcUNGA81 and rcUNGA81o where 74 and 81 of the N-terminal amino acids were removed, respectively. These have the same length as the human Δ77 and Δ84 respectively (64). The Δ74o and Δ81o constructs have the codons encoding arginine 87 and 88 optimized for expression in *E. coli*, by changing them from AGA to CGT. All constructs were made by PCR as described above, using the following primers and template: rcUNGA74: UDGL77 (5'-ACCATGGAATTCGCAAAAGCAACGCCTGCA-3') and UDGEN2 (5'-GAGCTCGTCTGACTTAGAGTGCTCTCCAGTTTATAGG-3') and 10 ng cDNA as template. rcUNGA81: UDGL84 (5'-ACCATGGAATTCTTCGGAGAGACTTGGAGAAGA-3') and UDGEN2 and 10 ng cDNA as template. rcUNGA74o: (5'-ATGGAATTCGCAAAAGCAACGCCTGCAGGTTTCGGAGAGACTTGGCGTCGTGAG-3') and UDGEN2 and 1 ng rcUNGA81o as template. rcUNGA81o: (5'-ATGGAATTCCTTCGGAGAGACTTGGCGTCGTGAGCTGGCTGC-3') and UDGEN2 and 10 ng cDNA as template.

Small Scale Expression Of Uracil-DNA Glycosylase

Optimization of expression were done in 11 baffled erlenmeyer flasks with 100 ml LB+ medium with 100 µg/ml ampicillin, inoculated with 5 ml of preculture. Cells were
5 induced with 1 mM of IPTG at OD600 = 2.0, and induced at various length as indicated in figure legends. Expression was examined using various temperatures (20 °C, 25 °C, 30 °C and 37 °C).

Fermentation Conditions

10 Fermentation was done in a 10 l Chemap CF 3000 fermentor (Switzerland). A 200 ml preculture of *E.coli* NR8052 with the pTrc99A oΔ84 construct was inoculated to 7 l of LB-medium supplemented with 20 mM glucose and 100 µg/ml ampicillin. Cells were grown to an OD600 of 2.0 and induced
15 for 8 h with 1 mM IPTG. Additional glucose (3 x 50 ml of 20% glucose (W/v)) was supplemented during the fermentation to avoid glucose starvation. Cells were harvested and centrifuged at 10.000 g for 10 minutes. The cell paste was frozen at -70 °C.

20 Purification Of Recombinant Cod UNG

Crude Extract

From the fermentation, 4 l of the *E. coli* NR8052 cells (68 g wet weight) were resuspended in 400 ml of extraction buffer (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1% glycerol,
25 1 mM DTT, 1 mM PMSF pH 8,0). The cells were disrupted by subjecting them five times through the Nebulizer using 100 psi of nitrogen. The cell extract was centrifuged 25.000 g for 10 min, and the supernatant removed. The pellet was
30 resuspended in 100 ml of buffer A, and recentrifuged as described above. The supernatants were combined and filtrated through glasswool (460 ml).

Protamine Sulphate

To the crude extract (460 ml), 60 ml of 2% protamine sulphate in buffer A (25 mM Tris/HCl, 10 mM NaCl, 1 mM EDTA, 1% glycerol, pH 8.0) was added and incubated at 4°C
5 for 5 min with stirring. The solution was centrifuged at 25,000 g for 10 min, and the supernatant was removed, 510 ml (Fraction 1).

Q/S-Sepharose

The protamine sulphate fraction was applied on a Q-
10 Sepharose column (5.0/10) coupled with a S-Sepharose column (2.6/10), both equilibrated in buffer A, using a flow rate of 10 ml/min. The columns were washed with 750 ml buffer A, and then the Q-Sepharose column was removed. The S-
15 Sepharose column was washed with an additional 550 ml buffer A + 60 mM NaCl, and a gradient from 60 to 400 mM NaCl in buffer A was applied to elute the column, using a flow rate of 5 ml/min. Fractions of 10 ml were collected, and fractions containing UNG-activity were pooled (Fraction 2, 115 ml).

20 Blue Sepharose FF

Fraction 2 was diluted two times in buffer A, and directly
-----applied to a Blue-Sepharose column (1.6/5.0), with a flow
rate of 4 ml/min. The column was then washed with 30 ml of
buffer A and 60 ml of buffer A + 110 mM NaCl, and eluted
25 with 60 ml buffer A + 0.7 M NaCl. UNG containing fractions were pooled (Fraction 3, 24 ml).

Superdex 75

Fraction 3 was concentrated to 3 ml using a Ultrafree 15 unit, (Millipore) and applied to the Superdex 75 column
30 (2.6/60) equilibrated in buffer A + 0.15 M NaCl. A flow rate of 2 ml/min was used, and fractions of 5 ml were

collected. Fractions containing UNG-activity were pooled (Fraction 4, 30 ml).

Source 15Q

The superdex 75 fraction was diafiltrated in a Ultrafree 15 unit (Millipore) and approximately 2/3 of the Superdex 75 fraction was applied to the Source 15Q column (2.6/3.0) equilibrated in buffer A at room temperature. The column was washed with 60 ml buffer A + 60 mM NaCl, and then a gradient from 60 to 210 mM NaCl in buffer A was applied to elute the column. Fractions were collected on ice, and UNG-containing fractions were pooled (UNG-activity eluted between 105 to 145 mM NaCl).

RESULTS

Sequence Of cUNG1 And cUNG2

15 cUNG1 DNA sequence and translated protein:

GACATCCGCTTGCAAATATGTTGTTCAAG

M L F K

TTAGGGTTATGCCAAAGATGCATATCATCAAATCGGGTYTTACCAGGTTTA

L G L C Q R C I S S N R V L P G L

20 CTAATTCCCCAAACTTTATGTTTTTCTAAATTAATGAAGATAACGCCGAAG

L I P Q T L C F S K L M K I T P K

40

50

AAACTGAGGTCCTCAAATGTGGAACAAAAGACGTCATCGCCACAGCTTTCA

K L R S S N V E Q K T S S P Q L S

25

60

70

GTGGAGCAGCTGGAAAGAATGGCCAAAAATAAGAAAGCAGCGCTTGACAAG

V E Q L E R M A K N K K A A L D K

80

ATTAGAGCAAAAGCAACGCCTGCAGGTTTCGGAGAGACTTGGAGAAGAGAG
I R A K A T P A G F G E T W R R E
90

CTGGCTGCAGAGTTTGAAAAGCCATACTTCAAACAATTGATGTCCTTTGTA
5 L A A E F E K P Y F K Q L M S F V

GCTGATGAGAGGAGCCGTCACACCGTCTACCCACCGGCTGATCAAGTGTAC
A D E R S R H T V Y P P A D Q V Y

AGTTGGACAGAGATGTGTGACATTCAAGATGTGAAAGTAGTGATTCTAGGC
S W T E M C D I Q D V K V V I L G

10 CAGGACCCTTACCACGGTCCCAACCAAGCACATGGACTCTGTTTCAGTGTG
Q D P Y H G P N Q A H G L C F S V

CAAAAGCCAGTTCCCCCTCCCCCAGTCTCGTGAACATATACAAAGAATTG
Q K P V P P P P S L V N I Y K E L

15 TGTACCGACATTGATGGCTTCAAGCATCCTGGACATGGAGATCTAAGCGGA
C T D I D G F K H P G H G D L S G

TGGGCAAAACAAGGGGTGCTGCTGCTTAACGCGGTGCTGACCGTGCGGGCC
W A K Q G V L L L N A V L T V R A

CATCAGGCCAACTCCCACAAGGACAGAGGCTGGGAGACCTTCACCGACGCT
H Q A N S H K D R G W E T F T D A

20 GTGATCAAGTGGCTGAGCGTCAACCGGGAAGGAGTGGTTTTCTGTTGTGG
V I K W L S V N R E G V V F L L W

GGCTCATACGCCCATAAGAAGGGAGCGACCATCGACAGGAAACGTCACCAT
G S Y A H K K G A T I D R K R H H

25 GTCTTGCAAGCTGTTTCATCCATCTCCTTTGTCTGCTCATCGTGGGTTCTT
V L Q A V H P S P L S A H R G F L

GGTTGTAAGCACTTCTCCAAGGCTAACGGGCTGCTGAAACTATCTGGGACG
G C K H F S K A N G L L K L S G T

GAGCCTATAAACTGGAGAGCACTCTAACTCTTTATGCTGCCTTATACTGTT
E P I N W R A L *

5 AACTGTTTTAAGATGAACATCACACTATATTTTCTACAGCTTTTCCAAGTT

CAAACCAATCTATAAGCTTTCATTTGTCTTTTGAATGATGCTGCTTTTGG

TCGGTTTTAGATACTTAAAACACTTTACCACTCTGCCATGTTGACTCATGT

TCAGTCAATATAACTTTCACAACCTGAACAAAAATGTTATTTTATAATTGA

TTATATTCTGTACATTAAAGATTGTTTTTTTCCCAGGCTGTTTCATAGGTA

10 CTAGGATATTAAACTGTTATTAACCTATTTTCCATGATGTCAACTGCTTAA

GTTTTTATGCAGAAATAAATTATATATTTA

cUNG2 DNA Sequence And Translated Protein:

GATGGTTTAGGAGGATAGTACTTTGACACTGGTTAGCGAAGGGGAAAACG

1

15 GAGTTATTGTGCATATCGTTTTAGCCCTACGTTTAAAAAATGATTGGTCAA

M I G Q

10

20

CAGCATATCAACTCTTTCTTCTCACCAGTTTCAAAAAAGAGAGTTTCAAAG

Q H I N S F F S P V S K K R V S K

20

30

GAATTAGGTAAAACCGAAAAGCATGCCGAAGAAGTTCAGATAACGCCGAAG

E L G K T E K H A E E V Q I T P K

40

50

AAACTGAGGTCCTCAAATGTGGAACAAAAGACGTCATCGCCACAGCTTTCA
K L R S S N V E Q K T S S P Q L S
60 70

GTGGAGCAGCTGGAAAGAATGGCCAAAAATAAGAAAGCAGCGCTTGACAAG
5 V E Q L E R M A K N K K A A L D K
80

ATTAGAGCAAAGCAACGCCTGCAGGTTTCGGAGAGACTTGGAGAAGAGAG
I R A K A T P A G F G E T W R R E
90

10 CTGGCTGCAGAGTTTGAAAAGCCATACTTCAAACAATTGATGTCCTTTGTA
L A A E F E K P Y F K Q L M S F V

GCTGATGAGAGGAGCCGTCACACCGTCTACCCACCGGCTGATCAAGTGTAC
A D E R S R H T V Y P P A D Q V Y

AGTTGGACAGAGATGTGTGACATTCAAGATGTGAAAGTAGTGATTCTAGGC
15 S W T E M C D I Q D V K V V I L G

CAGGACCCTTACCACGGTCCCAACCAAGCACATGGACTCTGTTTCAGTGTG
Q D P Y H G P N Q A H G L C F S V

CAAAAGCCAGTTCCCCCTCCCCCAGTCTCGTGAACATATACAAAGAATTG
Q K P V P P P P S L V N I Y K E L

20 TGTACCGACATTGATGGCTTCAAGCATCCTGGACATGGAGATCTAAGCGGA
C T D I D G F K H P G H G D L S G

TGGGCAAAACAAGGGGTGCTGCTGCTTAACGCGGTGCTGACCGTGCGGGCC
W A K Q G V L L L N A V L T V R A

CATCAGGCCAACTCCCACAAGGACAGAGGCTGGGAGACCTTCACCGACGCT
25 H Q A N S H K D R G W E T F T D A

GTGATCAAGTGGCTGAGCGTCAACCGGGAAGGAGTGGTTTTCTGTTGTGG
V I K W L S V N R E G V V F L L W

GGCTCATACGCCATAAGAAGGGAGCGACCATCGACAGGAAACGTCACCAT
G S Y A H K K G A T I D R K R H H

GTCTTGCAAGCTGTTTCATCCATCTCCTTTGTCTGCTCATCGTGGGTTTCCTT
V L Q A V H P S P L S A H R G F L

5 GGTGTAAGCACTTCTCCAAGGCTAACGGGCTGCTGAAACTATCTGGGACG
G C K H F S K A N G L L K L S G T

GAGCCTATAAACTGGAGAGCACTCTAACTCTTTATGCTGCCTTATACTGTT
E P I N W R A L *

AACTGTTTTTAAGATGAACATCACACTATATTTTCTACAGCTTTTCCAAGTT

10 CAAACCAATCTATAAGCTTTCATTTGTCTTTTGGAATGATGCTGCTTTTGG

TCGGTTTTAGATACTTAAAACACTTTACCACTCTGCCATGTTGACTCATGT

TCAGTCAATATAACTTTCACAACCTGAACAAAATGTTATTTTATAATTGA

TTATATTCTGTACATTAAAGATTGTTTTTTTCCCAGGCTGTTTCATAGGTA

CTAGGATATTAAACTGTTATTAACTTATTTTCCATGATGTCAACTGCTTAA

15 GTTTTTATGCAGAAATAAATTATATATTTA

Expression

Expression of rcUNG by the pTrc99A-Δ810 construct in 7L scale fermentation yielded a total of 413,480 Units of rcUNG contained in the crude extract.

20 Purification

Purification of recombinant cUNG (Δ810) (rcUNG) is summarized in table 1. From 4 l of the fermentation batch, 4.8 mg of recombinant UNG was purified to apparent homogeneity, and the molecular weight was determined to 28

kD by SDS-PAGE. The specific activity of the enzyme was determined to 30092 U/mg using the nick-generated substrate with standard assay conditions.

Characterization

5 The recombinant cod UNG was found to be similar to the native cUNG, previously purified from cod liver. The pH-optimum was found to be slightly lower than the native cUNG, with a peak activity at pH 7.0 and 50 mM NaCl. The pH- and temperature stability was found to be almost
10 identical to the native cUNG, with a maximal stability at pH 7.5 and half-lives of 0.5 min at 50 °C, 20 min at 37 °C, 80 min at 25 °C and 1.6 h at 4 °C.

Example: Carry Over Prevention

Method

15 As a contaminant, 0.5 ng of uracil-containing template DNA (761 bp fragment generated from cationic trypsinogen from Atlantic salmon (*Salmo salar*) (61)) was added to the PCR-mix in a final volume of 50 µl, containing 10 mM Tris/HCl pH 9.0 (25°C), 50 mM KCl, 0.1% Triton X-100, 10 ng cDNA,
20 0.2 mM dATP, dCTP, dGTP and dTTP respectively, 2.0 µM upstream- (OP5) and downstream primer (NP2) respectively and 1.0 U Taq-polymerase (Promega). UNG (4×10^{-3} or 1.7×10^{-2} U) was added to the PCR-mix and incubated at RT for 10 minutes.

25 As negative controls, one PCR reaction mixture contained template with thymidine replacing uracil, and in one mixture water replaced UNG. Also, as a positive control 1.7×10^{-3} U UNG from *E. coli* was used.

Then PCR was carried out by 94°C for 4 min, 30 cycles of
30 94°C for 1 min, 60°C for 1 min and 72°C for 1 min. After the

PCR the products were analyzed by agarose gel electrophoresis.

PCR primer sequences:

OP5:

5' -TCTCTCGAGAAAAGAGAGGCTGAAGCTCCCATTGACGATGAGGATGA-3'

NP2:

5' -GTAGAATTCCGATCCATGTCTCCTCCAGTCTAGAT-3'

Result

The result of the experiment according to the example is shown in fig. 9. The uracil-containing templates were degraded by UNG in all PCR reactions while the reactions either without UNG or with thymine-containing templates yielded the expected PCR product. The results in fig. 9 are shown as a figure of an agarose gel.

Table 1: Purification Of Atlantic Cod Liver Uracil-DNA Glycosylase (cUNG).

Step	Volume (ml)	Activity _a (U/ml)	Total activity (U)	Protein conc (mg/ml) _b	Total protein (mg)	Specific activity (U/mg)	Yield (%)	Purification Fold
Crude extract	2000	0.086	172	4	8000	0.021	100	1
Q-Sepharose FF	2340	0.073	170	1.66	3884	0.044	99	2
S-Sepharose FF	55	1.796	98.8	0.155	8.53	11.6	58	540
Heparin Sepharose	20	2.775	55.5	0.081	1.62	34.3	32	1597
Poly-U Sepharose	70	0.446	31.2	ND _c	ND	ND	18	ND
Superdex75	3	1.138	3.41	0.003	0.009	379	2	17679

- a) Enzyme activity was measured as described under standard assay in material and methods using nick-substrate.
- b) Protein concentration was determined as described in material and methods.
- c) Protein concentration was too low to determine.

Table 2: Substrate specificity ssDNA versus dsDNA.

Substrate	Cpm	Activity (%)	Fold increase
dsNick	586	100	1.0
ssNick	1078	183	1.8
dsPCR	1158	100	1.0
ssPCR	2214	191	1.9

Figure 1 shows pI determination of Atlantic cod UNG (cUNG). Following the isoelectric focusing using Phast Gel IEF 3-9, the gel was cut in pieces of 2 mm. Each piece was transferred to an eppendorf tube and incubated overnight at 4 °C. Activity was then measured as described in material and methods.

Figure 2 shows product inhibition of cUNG with free uracil. Different concentrations of uracil was added to the assay mixture and the assay performed as described in material and methods.

Figure 3 shows inhibition of cUNG with the *Bacillus subtilis* bacteriophage uracil-DNA glycosylase inhibitor (Ugi). 6.65×10^{-4} U of cUNG was incubated with 1.25×10^3 U to 2.00×10^2 U of Ugi using standard assay conditions, as described in material and methods. One Unit of Ugi inhibit one Unit of UNG-activity, where the UNG-activity is defined as releasing 60 pmol of uracil per min at 37°C.

Figure 4 shows pH and NaCl optimum of cUNG. Activity of cUNG was measured with variable sodium chloride

concentrations in different pH-series, as described in material and methods. The percent UNG activity is set relative to the highest value measured, pH 7.5 with 50 mM NaCl.

5 Figure 5 shows temperature optimum of cUNG. Due to prolonged incubation of the enzyme sample on ice during the experiment, activity is corrected with respect to the stability of the enzyme, as described in material and methods.

10 Figure 6 shows Temperature profile of cUNG (▲) and rhUNG (■). Enzyme activity was measured as described in material and methods. The percent UNG activity is set relative to the highest value for cUNG (45°C) and rhUNG (50°C) respectively. Due to prolonged incubation of the enzyme
15 samples on ice during the experiment, activity is corrected with respect to the stability of the enzymes, as described in material and methods.

Figure 7 shows pH stability of Atlantic cod UNG (cUNG) and recombinant human UNG (rhUNG). In the different pH-buffers,
20 0.01 U of cUNG (▲) or rhUNG (■) were incubated for 10 minutes at 37°C. Then 5 µl aliquotes were transferred to the assay mixture, and residual activity was measured using standard assay conditions as described in materials and methods. One hundred percent activity was measured directly
25 from a sample diluted at pH 8.0 without any incubation step.

Figure 8 shows temperature stability of Atlantic cod UNG (cUNG) (▲) and recombinant human UNG (rhUNG) (■). Enzyme (0.01 U) were incubated at 50°C, 37°C, 25°C and 4°C, and 5 µ
30 aliquotes were transferred to the assay mixture after different time intervals, and standard assays were performed as described in material and methods. Half-lives were determined to 0.5 min (50°C), 20 min (37°C), 60 min

(25°C) and 2 h (4°C) for cUNG and 8 min (50°C) , 30 min (37°C), 150 min (25°C) and 2.6 h (4°C) for rhUNG.

Figure 9 shows agarose gel showing PCR products from carry-over prevention test using recombinant Cod UNG (rcUNG).

- 5 Lane descriptions: lanes 1 and 8: DNA ladder; lane 2: T-containing template, no UNG; lane 3: T-containing template, 1.7×10^{-3} U rcUNG; lane 4: U-containing template, 4×10^{-4} U rcUNG; lane 5: U-containing template, 1.7×10^{-3} U rcUNG; lane 6: U-containing template, 4×10^{-4} U *E. coli* UNG; lane
10 7: U-containing template, no UNG.

References:

- (1) Lindahl T. Proc Natl Acad Sci U S A 1974;71:3649-53.
- (2) Lindahl T. Prog Nucleic Acid Res Mol Biol 1979;22:135-92.
- 15 (3) Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Embo J 1996;15:6662-70.
- (4) Nicholl ID, Nealon K, Kenny MK. Biochemistry 1997;36:7557-66.
- (5) Parikh SS, Mol CD, Tainer JA. Structure 1997;5:1543-50.
-
- 20 (6) Slupphaug G, Olsen LC, Helland D, Aasland R, Krokan HE. Nucleic Acids Res 1991;19:5131-7.
- (7) Muller SJ, Caradonna S. Biochim Biophys Acta 1991;1088:197-207.
- (8) Muller Weeks SJ, Caradonna S. Exp Cell Res 1996;226:346-
25 55.
- (9) Haushalter KA, Todd Stukenberg MW, Kirschner MW, Verdine GL. Curr Biol 1999;9:174-85.

- (10) Gallinari P, Jiricny J. Nature 1996;**383**:735-8.
- (11) Barrett TE, Savva R, Panayotou G, Barlow T, Brown T, Jiricny J, Pearl LH. Cell 1998;**92**:117-29.
- (12) Sandigursky M, Franklin WA. Curr Biol 1999;**9**:531-4.
- 5 (13) Krokan HE, Standal R, Slupphaug G. Biochem J 1997;**325**:1-16.
- (14) Higley M, Lloyd RS. Mutat Res 1993;**294**:109-16.
- (15) Bennett SE, Sanderson RJ, Mosbaugh DW. Biochemistry 1995;**34**:6109-19.
- 10 (16) Purmal AA, Lampman GW, Pourmal EI, Melamede RJ, Wallace SS, Kow YW. J Biol Chem 1994;**269**:22046-53.
- (17) Colson P, Verly WG. Eur J Biochem 1983;**134**:415-20.
- (18) Domena JD, Mosbaugh DW. Biochemistry 1985;**24**:7320-8.
- (19) Domena JD, Timmer RT, Dicharry SA, Mosbaugh DW.
15 Biochemistry 1988;**27**:6742-51.
-
- (20) Seal G, Arenaz P, Sirover MA. Biochim Biophys Acta 1987;**925**:226-33.
- (21) Wittwer CU, Bauw G, Krokan HE. Biochemistry 1989;**28**:780-4.
- 20 (22) Krokan H, Wittwer CU. Nucleic Acids Res 1981;**9**:2599-613.
- (23) Wittwer CU, Krokan H. Biochim Biophys Acta 1985;**832**:308-18.
- (24) Myrnes B, Wittwer CU. Eur J Biochem 1988;**173**:383-7.

- (25) Caradonna S, Ladner R, Hansbury M, Kosciuk M, Lynch F, Muller S. Exp Cell Res 1996;222:345-59.
- (26) Muller-Weeks S, Mastran B, Caradonna S. J Biol Chem 1998;273:21909-17.
- 5 (27) Seal G, Tallarida RJ, Sirover MA. Biochim Biophys Acta 1991;1097:299-308.
- (28) Caradonna SJ, Cheng YC. J Biol Chem 1980;255:2293-300.
- (29) Talpaert-Borle M, Clerici L, Campagnari F. J Biol Chem 1979;254:6387-91.
- 10 (30) Talpaert-Borle M, Campagnari F, Creissen DM. J Biol Chem 1982;257:1208-14.
- (31) Guyer RB, Nonnemaker JM, Deering RA. Biochim Biophys Acta 1986;868:262-4.
- (32) Crosby B, Prakash L, Davis H, Hinkle DC. Nucleic Acids
15 Res 1981;9:5797-809.
- (33) Blaisdell P, Warner H. J Biol Chem 1983;258:1603-9.
- (34) Talpaert-Borle M, Liuzzi M. Eur J Biochem 1982;124:435-40.
-
- (35) Birch DJ, McLennan AG. Biochem Soc Trans 1980;8:730-1.
- 20 (36) Lindahl T, Ljungquist S, Siegert W, Nyberg B, Sperens B. J Biol Chem 1977;252:3286-94.
- (37) Cone R, Duncan J, Hamilton L, Friedberg EC. Biochemistry 1977;16:3194-201.
- (38) Williams MV, Pollack JD. J Bacteriol 1990;172:2979-85.

- (39) Kaboev OK, Luchkina LA, Akhmedov AT, Bekker ML. FEBS Lett 1981;132:337-40.
- (40) Purnapatre K, Varshney U. Eur J Biochem 1998;256:580-8.
- (41) Kaboev OK, Luchkina LA, Kuziakina TI. J Bacteriol
5 1985;164:421-4.
- (42) Masters CI, Moseley BE, Minton KW. Mutat Res 1991;254:263-72.
- (43) Koulis A, Cowan DA, Pearl LH, Savva R. FEMS Microbiol Lett 1996;143:267-71.
- 10 (44) Leblanc JP, Martin B, Cadet J, Laval J. J Biol Chem 1982;257:3477-83.
- (45) Sobek H, Schmidt M, Frey B, Kaluza K. FEBS Lett 1996;388:1-4.
- (46) Focher F, Verri A, Spadari S, Manservigi R, Gambino J,
15 Wright GE. Biochem J 1993;292:883-9.
- (47) Winters TA, Williams MV. Virology 1993;195:315-26.
- (48) Slupphaug G, Markussen FH, Olsen LC, Aasland R,
~~Aarsaether N, Bakke O, Krokan HE, Helland DE. Nucleic~~
Acids Res 1993;21:2579-84.
- 20 (49) Nilsen H, Otterlei M, Haug T, Solum K, Nagelhus TA, Skorpen F, Krokan HE. Nucleic Acids Res 1997;25:750-5.
- (50) Bharati S, Krokan HE, Kristiansen L, Otterlei M, Slupphaug G. Nucleic Acids Res 1998;26:4953-9.
- (51) Haug T, Skorpen F, Aas PA, Malm V, Skjelbred C, Krokan
25 HE. Nucleic Acids Res 1998;26:1449-57.

- (52) Otterlei M, Haug T, Nagelhus TA, Slupphaug G, Lindmo T, Krokan HE. Nucleic Acids Res 1998;26:4611-7.
- (53) Mol CD, Arvai AS, Slupphaug G, Kavli B, Alseth I, Krokan HE, Tainer JA. Cell 1995;80:869-78.
- 5 (54) Savva R, McAuley Hecht K, Brown T, Pearl L. Nature 1995;373:487-93.
- (55) Ravishankar R, Bidya Sagar M, Roy S, Purnapatre K, Handa P, Varshney U, Vijayan M. Nucleic Acids Res 1998;26:4880-7.
- 10 (56) Slupphaug G, Mol CD, Kavli B, Arvai AS, Krokan HE, Tainer JA. Nature 1996;384:87-92.
- (57) Parikh SS, Mol CD, Slupphaug G, Bharati S, Krokan HE, Tainer JA. Embo J 1998;17:5214-26.
- (58) Feller G, Gerday C. Cell Mol Life Sci 1997;53:830-41.
- 15 (59) Kwok S, Higuchi R. Nature 1989;339:237-8.
- (60) Longo MC, Berninger MS, Hartley JL. Gene 1990;93:125-8.
- (61) Male R, Lorens JB, Smalas AO, Torrissen KR. Eur J Biochem 1995;232:677-85.
- (62) Wang KT, Wang IS. Biochim Biophys Acta 1967;142:280-1.
- 20 (63) Bradford MM. Anal Biochem 1976;72:248-54.
- (64) Slupphaug G, Eftedal I, Kavli B, Bharati S, Helle NM, Haug T, Levine DW, Krokan HE. Biochemistry 1995;34:128-38.
- (65) Bennett SE, Schimerlik MI, Mosbaugh DW. J Biol Chem 25 1993;268:26879-85.

- (66) Karran P, Cone R, Friedberg EC. Biochemistry 1981;20:6092-6.
- (67) Mol CD, Arvai AS, Sanderson RJ, Slupphaug G, Kavli B, Krokan HE, Mosbaugh DW, Tainer JA. Cell 1995;82:701-8.
- 5 (68) Savva R, Pearl LH. Nat Struct Biol 1995;2:752-7.
- (69) Lohman TM. CRC Crit Rev Biochem 1986;19:191-245.
- (70) von Hippel PH, Berg OG. J Biol Chem 1989;264:675-8.
- (71) Dodson ML, Michaels ML, Lloyd RS. J Biol Chem 1994;269:32709-12.
- 10 (72) Hamilton RW, Lloyd RS. J Biol Chem 1989;264:17422-7.
- (73) Outzen H, Berglund GI, Smalas AO, Willassen NP. Comp Biochem Physiol B Biochem Mol Biol 1996;115:33-45.
- (74) Berglund GI, Smalas AO, Outzen H, Willassen NP. Mol Mar Biol Biotechnol 1998;7:105-14.
- 15 (75) Kunkel TA. Proc Natl Acad Sci U S A 1985;82:488-92.
- (76) Varshney U, van de Sande JH. Nucleic Acids Res 1989;17:813.
-
- (77) Amann E, Ochs B, Abel KJ. Gene 1988;69:301-15.



C l a i m s

1. Enzyme,
c h a r a c t e r i z e d i n that it has UDG activity
and is completely deactivated when heated above 60°C.
- 5 2. Enzyme according to claim 1,
c h a r a c t e r i z e d i n that it has an amino acid
sequence as shown in ~~Fig. 1~~ or a functional part thereof.
3. Enzyme according to claim 1 or 2,
c h a r a c t e r i z e d i n that it is derived from
10 an organism adapted to a cold environment.
4. Enzyme according to any of the preceding claims,
c h a r a c t e r i z e d i n that it is derived from
Atlantic cod (*Gadus morhua*).
5. Enzyme accordig to any of the preceding claims,
15 c h a r a c t e r i z e d i n that it includes a
traceable label.
6. DNA sequence,
c h a r a c t e r i z e d i n that it codes for the
enzyme according to any of the claims 1 - 5.
- 20 7. DNA sequence,
c h a r a c t e r i z e d i n that it comprises the
nucleotide sequence given in ~~SEQ ID No. 1~~.
8. DNA sequence according to claim 6 or 7,
c h a r a c t e r i z e d i n that it includes a
25 promoter.
9. DNA sequence according to claim 6, 7 or 8,
c h a r a c t e r i z e d i n that it is contained in
an expression vector, e.g. a plasmid, a cosmid or a virus.

10. DNA sequence according to any of the claims 6 - 9,
c h a r a c t e r i z e d i n that it includes a
traceable label.

11. Microorganism,
5 c h a r a c t e r i z e d i n that it includes a DNA
sequence accordig to any of the claims 6 - 10.

12. Microorganism according to claim 11,
c h a r a c t e r i z e d i n that it is a mammalian
cell or a bacterium.

10 13. Microorganism according to claim 11 or 12,
c h a r a c t e r i z e d i n that it is an *E. coli*
strain.

14. Use of an enzyme according to any of the claims 1 - 5
in monitoring an/or controlling a reaction system
15 multiplying DNA sequences, e.g. PCR or LCR.

15. Use of an enzyme according to any of the claims 1 - 5
in carry-over prevention procedures.



A b s t r a c t

It is disclosed a novel enzyme present in cod liver, a DNA sequence encoding the enzyme or operative parts thereof, a novel recombinant DNA comprising the gene or the operative parts thereof, a method of preparing the enzyme from cod liver and from bacteria carrying the gene, the bacteria carrying the gene per se, and the use of the protein in monitoring and/or controlling PCR or related reaction systems.






Fig. 1






Fig. 2






Fig. 3







Fig. 4







Fig. 5







Fig. 6







Fig. 7









Fig. 8






Fig. 9

